Granulocytic	O
differentiation	O
of	O
human	B-cell_type
NB4	I-cell_type
promyelocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
induced	O
by	O
all-trans	O
retinoic	O
acid	O
metabolites	O
.	O

The	O
metabolism	O
of	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
has	O
been	O
reported	O
to	O
be	O
partly	O
responsible	O
for	O
the	O
in	O
vivo	O
resistance	O
to	O
ATRA	O
seen	O
in	O
the	O
treatment	O
of	O
human	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

However	O
,	O
ATRA	O
metabolism	O
appears	O
to	O
be	O
involved	O
in	O
the	O
growth	O
inhibition	O
of	O
several	O
cancer	B-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
vitro	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
in	O
vitro	O
activity	O
of	O
the	O
principal	O
metabolites	O
of	O
ATRA	O
[	O
4-hydroxy-retinoic	O
acid	O
(	O
4-OH-RA	O
)	O
,	O
18-hydroxy-retinoic	O
acid	O
(	O
18-OH-RA	O
)	O
,	O
4-oxo-retinoic	O
acid	O
(	O
4-oxo-RA	O
)	O
,	O
and	O
5	O
,	O
6-epoxy-retinoic	O
acid	O
(	O
5	O
,	O
6-epoxy-RA	O
)	O
]	O
in	O
NB4	B-cell_line
,	I-cell_line
a	I-cell_line
human	I-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
that	O
exhibits	O
the	O
APL	O
diagnostic	O
t	O
(	O
15	O
;	O
17	O
)	O
chromosomal	O
translocation	O
and	O
expresses	O
the	O
PML-RAR	B-protein
alpha	I-protein
fusion	I-protein
protein	I-protein
.	O

We	O
established	O
that	O
the	O
four	O
ATRA	O
metabolites	O
were	O
indeed	O
formed	O
by	O
the	O
NB4	B-cell_line
cells	I-cell_line
in	O
vitro	O
.	O

NB4	O
cell	O
growth	O
was	O
inhibited	O
(	O
69-78	O
%	O
at	O
120	O
h	O
)	O
and	O
cell	O
cycle	O
progression	O
in	O
the	O
G1	O
phase	O
(	O
82-85	O
%	O
at	O
120	O
h	O
)	O
was	O
blocked	O
by	O
ATRA	O
and	O
all	O
of	O
the	O
metabolites	O
at	O
1	O
microM	O
concentration	O
.	O

ATRA	O
and	O
its	O
metabolites	O
could	O
induce	O
NB4	B-cell_line
cells	I-cell_line
differentiation	O
with	O
similar	O
activity	O
,	O
as	O
evaluated	O
by	O
cell	O
morphology	O
,	O
by	O
the	O
nitroblue	O
tetrazolium	O
reduction	O
test	O
(	O
82-88	O
%	O
at	O
120	O
h	O
)	O
or	O
by	O
the	O
expression	O
of	O
the	O
maturation	B-protein
specific	I-protein
cell	I-protein
surface	I-protein
marker	I-protein
CD11c	I-protein
.	O

In	O
addition	O
,	O
nuclear	O
body	O
reorganization	O
to	O
macropunctated	O
structures	O
,	O
as	O
well	O
as	O
the	O
degradation	O
of	O
PML-RAR	B-protein
alpha	I-protein
,	O
was	O
found	O
to	O
be	O
similar	O
for	O
ATRA	O
and	O
all	O
of	O
its	O
metabolites	O
.	O

Comparison	O
of	O
the	O
relative	O
potency	O
of	O
the	O
retinoids	O
using	O
the	O
nitroblue	O
tetrazolium	O
reduction	O
test	O
showed	O
effective	O
concentrations	O
required	O
to	O
differentiate	O
50	O
%	O
of	O
cells	O
in	O
72	O
h	O
as	O
follows	O
:	O
ATRA	O
,	O
15.8	O
+/-	O
1.7	O
nM	O
;	O
4-oxo-RA	O
,	O
38.3	O
+/-	O
1.3	O
nM	O
;	O
18-OH-RA	O
,	O
55.5	O
+/-	O
1.8	O
nM	O
;	O
4-OH-RA	O
,	O
79.8	O
+/-	O
1.8	O
nM	O
;	O
and	O
5	O
,	O
6-epoxy-RA	O
,	O
99.5	O
+/-	O
1.5	O
nM	O
.	O

The	O
ATRA	O
metabolites	O
were	O
found	O
to	O
exert	O
their	O
differentiation	O
effects	O
via	O
the	O
RAR	B-protein
alpha	I-protein
nuclear	I-protein
receptors	I-protein
,	O
because	O
the	O
RAR	O
alpha-specific	O
antagonist	O
BMS614	O
blocked	O
metabolite-induced	O
CD11c	O
expression	O
in	O
NB4	B-cell_line
cells	I-cell_line
.	O

These	O
data	O
demonstrate	O
that	O
the	O
principal	O
ATRA	O
Phase	O
1	O
metabolites	O
can	O
elicit	O
leukemia	B-cell_type
cell	I-cell_type
growth	O
inhibition	O
and	O
differentiation	O
in	O
vitro	O
through	O
the	O
RAR	O
alpha	O
signaling	O
pathway	O
,	O
and	O
they	O
suggest	O
that	O
these	O
metabolites	O
may	O
play	O
a	O
role	O
in	O
ATRA	O
antileukemic	O
activity	O
in	O
vivo	O
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
61	NULL
,	NULL
700-705	NULL
,	NULL
January	NULL
15	NULL
,	NULL
2001	NULL
]	NULL
Granulocytic	NULL
Differentiation	NULL
of	NULL
Human	NULL
NB4	NULL
Promyelocytic	NULL
Leukemia	NULL
Cells	NULL
Induced	NULL
by	NULL
All-frans	NULL
Retinoic	NULL
Acid	NULL
Metabolites	NULL
Nadia	NULL
Idres	NULL
,	NULL
Gérard	NULL
Benoit	NULL
,	NULL
Maria	NULL
A.	NULL
Flexor	NULL
,	NULL
Michel	NULL
Lanotte	NULL
,	NULL
and	NULL
Guy	NULL
G.	NULL
Chabot	NULL
``	NULL
Institut	NULL
National	NULL
de	NULL
la	NULL
Santé	NULL
et	NULL
de	NULL
la	NULL
Recherche	NULL
Médicale	NULL
(	NULL
INSERM	NULL
U496	NULL
)	NULL
,	NULL
Institut	NULL
Universitaire	NULL
d'Hématologie	NULL
(	NULL
Université	NULL
Paris	NULL
7	NULL
)	NULL
,	NULL
Hopital	NULL
Saint-Louis	NULL
(	NULL
AP-HP	NULL
)	NULL
,	NULL
75475	NULL
Paris	NULL
(	NULL
Cedex	NULL
10	NULL
)	NULL
,	NULL
France	NULL
ABSTRACT	NULL
The	NULL
metabolism	NULL
of	NULL
all-frans	NULL
retinoic	NULL
acid	NULL
(	NULL
ATRA	NULL
)	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
partly	NULL
responsible	NULL
for	NULL
the	NULL
in	NULL
vivo	NULL
resistance	NULL
to	NULL
ATRA	NULL
seen	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
human	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
.	NULL

However	NULL
,	NULL
ATRA	NULL
metabolism	NULL
appears	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
growth	NULL
inhibition	NULL
of	NULL
several	NULL
cancer	NULL
cell	NULL
lines	NULL
in	NULL
vitro	NULL
.	NULL

The	NULL
purpose	NULL
of	NULL
this	NULL
study	NULL
was	NULL
to	NULL
evaluate	NULL
the	NULL
in	NULL
vitro	NULL
activity	NULL
of	NULL
the	NULL
principal	NULL
metabolites	NULL
of	NULL
ATRA	NULL
[	NULL
4-hydroxy-retinoic	NULL
acid	NULL
(	NULL
4-0H-RA	NULL
)	NULL
,	NULL
18-hydroxy-retinoic	NULL
acid	NULL
(	NULL
18-OH-RA	NULL
)	NULL
,	NULL
4-oxo-retinoic	NULL
acid	NULL
(	NULL
4-0x0-RA	NULL
)	NULL
,	NULL
and	NULL
5,6-epoxy-retinoic	NULL
acid	NULL
(	NULL
5,6-epoxy-RA	NULL
)	NULL
]	NULL
in	NULL
NB4	NULL
,	NULL
a	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
that	NULL
exhibits	NULL
the	NULL
APL	NULL
diagnostic	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
chromosomal	NULL
translocation	NULL
and	NULL
expresses	NULL
the	NULL
PML-RARa	NULL
fusion	NULL
protein	NULL
.	NULL

We	NULL
established	NULL
that	NULL
the	NULL
four	NULL
ATRA	NULL
metabolites	NULL
were	NULL
indeed	NULL
formed	NULL
by	NULL
the	NULL
NB4	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

NB4	NULL
cell	NULL
growth	NULL
was	NULL
inhibited	NULL
(	NULL
69-78	NULL
%	NULL
at	NULL
120	NULL
h	NULL
)	NULL
and	NULL
cell	NULL
cycle	NULL
progression	NULL
in	NULL
the	NULL
G	NULL
,	NULL
phase	NULL
(	NULL
82-85	NULL
%	NULL
at	NULL
120	NULL
h	NULL
)	NULL
was	NULL
blocked	NULL
by	NULL
ATRA	NULL
and	NULL
all	NULL
of	NULL
the	NULL
metabolites	NULL
at	NULL
1	NULL
JLM	NULL
concentration	NULL
.	NULL

ATRA	NULL
and	NULL
its	NULL
metabolites	NULL
could	NULL
induce	NULL
NB4	NULL
cells	NULL
differentiation	NULL
with	NULL
similar	NULL
activity	NULL
,	NULL
as	NULL
evaluated	NULL
by	NULL
cell	NULL
morphology	NULL
,	NULL
by	NULL
the	NULL
nitroblue	NULL
tetrazolium	NULL
reduction	NULL
test	NULL
(	NULL
82-88	NULL
%	NULL
at	NULL
120	NULL
h	NULL
)	NULL
or	NULL
by	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
maturation	NULL
specific	NULL
cell	NULL
surface	NULL
marker	NULL
CD1c	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
nuclear	NULL
body	NULL
reorganization	NULL
to	NULL
macropunctated	NULL
structures	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
degradation	NULL
of	NULL
PML-RARa	NULL
«	NULL
,	NULL
was	NULL
found	NULL
to	NULL
be	NULL
similar	NULL
for	NULL
ATRA	NULL
and	NULL
all	NULL
of	NULL
its	NULL
metabolites	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
relative	NULL
potency	NULL
of	NULL
the	NULL
retinoids	NULL
using	NULL
the	NULL
nitroblue	NULL
tetrazolium	NULL
reduction	NULL
test	NULL
showed	NULL
effective	NULL
concentrations	NULL
required	NULL
to	NULL
differentiate	NULL
50	NULL
%	NULL
of	NULL
cells	NULL
in	NULL
72	NULL
h	NULL
as	NULL
follows	NULL
:	NULL
ATRA	NULL
,	NULL
15.8	NULL
+	NULL
1.7	NULL
nM	NULL
;	NULL
4-0xo-RA	NULL
,	NULL
38.3	NULL
+	NULL
1.3	NULL
nm	NULL
;	NULL
18-OH-RA	NULL
,	NULL
55.5	NULL
+	NULL
1.8	NULL
nM	NULL
;	NULL
4-0H-RA	NULL
,	NULL
79.8	NULL
+	NULL
1.8	NULL
nM	NULL
;	NULL
and	NULL
5,6-epoxy-RA	NULL
,	NULL
99.5	NULL
+	NULL
1.5	NULL
nm	NULL
.	NULL

The	NULL
ATRA	NULL
metabolites	NULL
were	NULL
found	NULL
to	NULL
exert	NULL
their	NULL
differentiation	NULL
effects	NULL
via	NULL
the	NULL
RARa	NULL
nuclear	NULL
receptors	NULL
,	NULL
because	NULL
the	NULL
RARa-specific	NULL
antagonist	NULL
BMS614	NULL
blocked	NULL
metabolite-induced	NULL
CD11¢	NULL
expression	NULL
in	NULL
NB4	NULL
cells	NULL
.	NULL

These	NULL
data	NULL
demonstrate	NULL
that	NULL
the	NULL
principal	NULL
ATRA	NULL
Phase	NULL
1	NULL
metabolites	NULL
can	NULL
elicit	NULL
leukemia	NULL
cell	NULL
growth	NULL
inhibition	NULL
and	NULL
differentiation	NULL
in	NULL
vitro	NULL
through	NULL
the	NULL
RARa	NULL
signaling	NULL
pathway	NULL
,	NULL
and	NULL
they	NULL
suggest	NULL
that	NULL
these	NULL
metabolites	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
ATRA	NULL
antileukemic	NULL
activity	NULL
in	NULL
vivo	NULL
.	NULL

INTRODUCTION	NULL
Retinoids	NULL
(	NULL
vitamin	NULL
A	NULL
or	NULL
retinol	NULL
,	NULL
and	NULL
its	NULL
derivatives	NULL
)	NULL
are	NULL
a	NULL
family	NULL
of	NULL
molecules	NULL
involved	NULL
in	NULL
many	NULL
physiological	NULL
processes	NULL
such	NULL
as	NULL
embry-ogenesis	NULL
,	NULL
cell	NULL
growth	NULL
,	NULL
vertebrate	NULL
development	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
homeostasis	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
retinoids	NULL
effects	NULL
are	NULL
known	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
two	NULL
classes	NULL
of	NULL
nuclear	NULL
receptors	NULL
,	NULL
the	NULL
RARs®	NULL
and	NULL
the	NULL
RXRs	NULL
,	NULL
each	NULL
comprising	NULL
three	NULL
subtypes	NULL
(	NULL
«	NULL
,	NULL
B	NULL
,	NULL
y	NULL
)	NULL
,	NULL
with	NULL
various	NULL
iso-	NULL
Received	NULL
5/16/00	NULL
;	NULL
accepted	NULL
11/14/00	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

Supported	NULL
by	NULL
the	NULL
Institut	NULL
National	NULL
de	NULL
la	NULL
Santé	NULL
et	NULL
de	NULL
la	NULL
Recherche	NULL
Médicale	NULL
(	NULL
IN-SERM	NULL
)	NULL
,	NULL
the	NULL
Centre	NULL
National	NULL
de	NULL
la	NULL
Recherche	NULL
Scientifique	NULL
(	NULL
CNRS	NULL
)	NULL
,	NULL
the	NULL
Association	NULL
pour	NULL
la	NULL
Recherche	NULL
sur	NULL
le	NULL
Cancer	NULL
(	NULL
ARC	NULL
,	NULL
Villejuif	NULL
)	NULL
,	NULL
and	NULL
the	NULL
Ligue	NULL
Nationale	NULL
Contre	NULL
le	NULL
Cancer	NULL
(	NULL
Paris	NULL
)	NULL
.	NULL

N.	NULL
I.	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
fellowship	NULL
from	NULL
the	NULL
Ministére	NULL
de	NULL
1'Education	NULL
Nationale	NULL
,	NULL
de	NULL
la	NULL
Recherche	NULL
et	NULL
de	NULL
la	NULL
Technologie	NULL
.	NULL

M.	NULL
F.	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
Association	NULL
Claude	NULL
Bernard	NULL
(	NULL
Paris	NULL
)	NULL
.	NULL

The	NULL
results	NULL
presented	NULL
herein	NULL
were	NULL
presented	NULL
in	NULL
part	NULL
at	NULL
the	NULL
91st	NULL
Annual	NULL
Meeting	NULL
of	NULL
the	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
,	NULL
April	NULL
1-5	NULL
,	NULL
2000	NULL
(	NULL
Proc	NULL
.	NULL

Am	NULL
.	NULL

Assoc	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
47	NULL
:	NULL
14	NULL
,	NULL
abstract	NULL
92	NULL
,	NULL
2000	NULL
)	NULL
.	NULL

*	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
,	NULL
at	NULL
Institut	NULL
Universitaire	NULL
d'Hématologie	NULL
,	NULL
INSERM	NULL
U496	NULL
,	NULL
Centre	NULL
Hayem	NULL
,	NULL
Hopital	NULL
Saint-Louis	NULL
,	NULL
1	NULL
avenue	NULL
Claude-Vellefaux	NULL
,	NULL
75475	NULL
Paris	NULL
(	NULL
Cedex	NULL
10	NULL
)	NULL
,	NULL
France	NULL
.	NULL

Phone	NULL
:	NULL
33-1-53-72-21-30	NULL
;	NULL
Fax	NULL
:	NULL
33-1-42-40-95-	NULL
57	NULL
;	NULL
E-mail	NULL
:	NULL
gchabot	NULL
@	NULL
chu-stlouis.fr	NULL
.	NULL

°	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
RAR	NULL
,	NULL
retinoic	NULL
acid	NULL
receptor	NULL
;	NULL
RA	NULL
,	NULL
retinoic	NULL
acid	NULL
;	NULL
APL	NULL
,	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
;	NULL
ATRA	NULL
,	NULL
all-trans	NULL
RA	NULL
;	NULL
4-O0H-RA	NULL
,	NULL
4-hydroxy-RA	NULL
;	NULL
18-OH-RA	NULL
,	NULL
18-hydroxy-RA	NULL
;	NULL
RXR	NULL
,	NULL
retinoids	NULL
X	NULL
receptor	NULL
;	NULL
CRABP	NULL
,	NULL
cellular	NULL
RA	NULL
binding	NULL
protein	NULL
;	NULL
forms	NULL
of	NULL
each	NULL
subtype	NULL
(	NULL
2	NULL
)	NULL
.	NULL

These	NULL
receptors	NULL
belong	NULL
to	NULL
the	NULL
superfamily	NULL
of	NULL
nuclear	NULL
hormone	NULL
receptors	NULL
and	NULL
act	NULL
as	NULL
ligand-activated	NULL
transcription	NULL
factors	NULL
of	NULL
numerous	NULL
genes	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

Retinoid	NULL
receptors	NULL
interact	NULL
as	NULL
either	NULL
homo-	NULL
or	NULL
heterodimers	NULL
on	NULL
specific	NULL
hormone	NULL
response	NULL
elements	NULL
(	NULL
RA	NULL
responsive	NULL
elements	NULL
or	NULL
RX	NULL
responsive	NULL
elements	NULL
)	NULL
of	NULL
target	NULL
gene	NULL
promoters	NULL
(	NULL
4-6	NULL
)	NULL
.	NULL

The	NULL
transcriptional	NULL
activity	NULL
of	NULL
these	NULL
receptors	NULL
is	NULL
further	NULL
positively	NULL
(	NULL
holo-receptor	NULL
)	NULL
or	NULL
negatively	NULL
(	NULL
apo-receptor	NULL
)	NULL
modulated	NULL
by	NULL
ligand	NULL
binding	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

7	NULL
and	NULL
8	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
intracellular	NULL
CRABPs	NULL
play	NULL
a	NULL
regulatory	NULL
function	NULL
in	NULL
RA	NULL
signaling	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Biological	NULL
responses	NULL
to	NULL
ATRA	NULL
may	NULL
,	NULL
therefore	NULL
,	NULL
be	NULL
modulated	NULL
by	NULL
the	NULL
type	NULL
of	NULL
nuclear	NULL
receptors	NULL
present	NULL
in	NULL
cells	NULL
,	NULL
by	NULL
nuclear	NULL
cofactors	NULL
,	NULL
by	NULL
the	NULL
CRABPs	NULL
,	NULL
and	NULL
by	NULL
the	NULL
availability	NULL
of	NULL
specific	NULL
retinoid	NULL
ligands	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

10	NULL
)	NULL
.	NULL

The	NULL
differentiating	NULL
properties	NULL
of	NULL
ATRA	NULL
have	NULL
led	NULL
to	NULL
the	NULL
development	NULL
of	NULL
therapies	NULL
for	NULL
the	NULL
prevention	NULL
and	NULL
treatment	NULL
of	NULL
various	NULL
human	NULL
cancers	NULL
(	NULL
11	NULL
)	NULL
including	NULL
APL	NULL
,	NULL
in	NULL
which	NULL
retinoids	NULL
are	NULL
particularly	NULL
active	NULL
(	NULL
12	NULL
)	NULL
.	NULL

APL	NULL
is	NULL
a	NULL
subtype	NULL
of	NULL
myeloid	NULL
leukemia	NULL
(	NULL
M3	NULL
)	NULL
,	NULL
characterized	NULL
by	NULL
the	NULL
accumulation	NULL
of	NULL
cells	NULL
blocked	NULL
at	NULL
the	NULL
promyelocytic	NULL
stage	NULL
.	NULL

This	NULL
leukemia	NULL
exhibits	NULL
a	NULL
specific	NULL
chromosomal	NULL
translocation	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
involving	NULL
the	NULL
PML	NULL
locus	NULL
on	NULL
chromosome	NULL
15	NULL
and	NULL
the	NULL
RARa	NULL
locus	NULL
on	NULL
chromosome	NULL
17	NULL
,	NULL
thus	NULL
generating	NULL
a	NULL
chimeric	NULL
gene	NULL
PML-RARa	NULL
,	NULL
translated	NULL
into	NULL
a	NULL
chimeric	NULL
nuclear	NULL
receptor	NULL
PML-RARa	NULL
(	NULL
13-17	NULL
)	NULL
.	NULL

PML-RARa	NULL
functions	NULL
as	NULL
an	NULL
aberrant	NULL
receptor	NULL
and	NULL
is	NULL
considered	NULL
to	NULL
be	NULL
the	NULL
cause	NULL
of	NULL
APL	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Although	NULL
several	NULL
clinical	NULL
studies	NULL
have	NULL
established	NULL
that	NULL
ATRA	NULL
can	NULL
induce	NULL
leukemia	NULL
cell	NULL
differentiation	NULL
and	NULL
remission	NULL
in	NULL
almost	NULL
all	NULL
patients	NULL
(	NULL
12	NULL
,	NULL
19	NULL
)	NULL
,	NULL
resistance	NULL
to	NULL
this	NULL
therapy	NULL
develops	NULL
rapidly	NULL
(	NULL
20	NULL
)	NULL
.	NULL

This	NULL
acquired	NULL
resistance	NULL
appears	NULL
to	NULL
be	NULL
attributable	NULL
in	NULL
part	NULL
to	NULL
the	NULL
decline	NULL
in	NULL
ATRA	NULL
plasma	NULL
levels	NULL
below	NULL
therapeutic	NULL
concentrations	NULL
after	NULL
repeated	NULL
administration	NULL
,	NULL
presumably	NULL
caused	NULL
by	NULL
the	NULL
induction	NULL
of	NULL
hepatic	NULL
cytochrome	NULL
P450s	NULL
that	NULL
may	NULL
increase	NULL
its	NULL
clearance	NULL
(	NULL
21-23	NULL
)	NULL
.	NULL

It	NULL
has	NULL
also	NULL
been	NULL
proposed	NULL
that	NULL
increased	NULL
CRABPs	NULL
contribute	NULL
to	NULL
resistance	NULL
by	NULL
decreasing	NULL
nuclear	NULL
availability	NULL
of	NULL
ATRA	NULL
(	NULL
24	NULL
)	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
mutations	NULL
in	NULL
the	NULL
E-ligand-binding	NULL
region	NULL
of	NULL
the	NULL
RARa	NULL
chimeric	NULL
protein	NULL
PML-RARa	NULL
have	NULL
been	NULL
linked	NULL
to	NULL
ATRA	NULL
resistance	NULL
(	NULL
25-29	NULL
)	NULL
.	NULL

ATRA	NULL
metabolism	NULL
is	NULL
complex	NULL
and	NULL
only	NULL
partially	NULL
understood	NULL
at	NULL
the	NULL
present	NULL
time	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

30	NULL
)	NULL
.	NULL

It	NULL
can	NULL
be	NULL
oxidized	NULL
by	NULL
cytochrome	NULL
P450s	NULL
to	NULL
various	NULL
metabolites	NULL
including	NULL
4-OH-RA	NULL
,	NULL
4-0x0-RA	NULL
,	NULL
18-OH-RA	NULL
,	NULL
and	NULL
5,6-epoxy-RA	NULL
,	NULL
which	NULL
may	NULL
be	NULL
further	NULL
metabolized	NULL
to	NULL
water-soluble	NULL
glucuronides	NULL
.	NULL

Although	NULL
ATRA	NULL
metabolites	NULL
are	NULL
often	NULL
considered	NULL
to	NULL
be	NULL
catabolic	NULL
products	NULL
possessing	NULL
low	NULL
biological	NULL
activity	NULL
,	NULL
some	NULL
metabolites	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
active	NULL
in	NULL
embryogenesis	NULL
and	NULL
to	NULL
inhibit	NULL
the	NULL
growth	NULL
of	NULL
certain	NULL
cancer	NULL
cell	NULL
lines	NULL
(	NULL
31-36	NULL
)	NULL
.	NULL

However	NULL
,	NULL
metabolism	NULL
also	NULL
seems	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
response	NULL
of	NULL
certain	NULL
cancer	NULL
cells	NULL
to	NULL
ATRA	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
a	NULL
study	NULL
of	NULL
breast	NULL
cancer	NULL
cell	NULL
lines	NULL
in	NULL
which	NULL
cell	NULL
lines	NULL
sensitive	NULL
to	NULL
ATRA	NULL
growth	NULL
inhibition	NULL
(	NULL
T47D	NULL
and	NULL
MCF7	NULL
)	NULL
could	NULL
metabolize	NULL
ATRA	NULL
to	NULL
polar	NULL
metabolites	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
4-0x0-RA	NULL
and	NULL
4-OH-RA	NULL
)	NULL
,	NULL
whereas	NULL
resistant	NULL
cell	NULL
lines	NULL
(	NULL
MDA-MB231	NULL
and	NULL
MDA-MB418	NULL
)	NULL
metabolized	NULL
ATRA	NULL
poorly	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
involving	NULL
ATRA	NULL
metabolism	NULL
to	NULL
polar	NULL
compounds	NULL
by	NULL
other	NULL
sensitive	NULL
cancer	NULL
cells	NULL
have	NULL
also	NULL
been	NULL
reported	NULL
(	NULL
37	NULL
)	NULL
.	NULL

HPLC	NULL
,	NULL
high-performance	NULL
liquid	NULL
chromatography	NULL
;	NULL
NBT	NULL
,	NULL
nitroblue	NULL
tetrazolium	NULL
;	NULL
NB	NULL
,	NULL
nuclear	NULL
body	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
;	NULL
PE	NULL
,	NULL
phycoerythrin	NULL
.	NULL

700	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
2001	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

DIFFERENTIATION	NULL
OF	NULL
NB4	NULL
CELLS	NULL
BY	NULL
ATRA	NULL
METABOLITES	NULL
As	NULL
the	NULL
metabolism	NULL
of	NULL
ATRA	NULL
appears	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
its	NULL
mechanism	NULL
of	NULL
action	NULL
in	NULL
certain	NULL
cancer	NULL
cell	NULL
lines	NULL
,	NULL
the	NULL
purpose	NULL
of	NULL
this	NULL
study	NULL
was	NULL
to	NULL
evaluate	NULL
the	NULL
in	NULL
vitro	NULL
effects	NULL
of	NULL
the	NULL
principal	NULL
oxidized	NULL
ATRA	NULL
metabolites	NULL
using	NULL
the	NULL
human	NULL
NB4	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
that	NULL
expresses	NULL
the	NULL
characteristic	NULL
APL	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
chromosomal	NULL
translocation	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
show	NULL
that	NULL
NB4	NULL
cells	NULL
can	NULL
metabolize	NULL
ATRA	NULL
to	NULL
polar	NULL
metabolites	NULL
(	NULL
4-OH-RA	NULL
,	NULL
4-0x0-RA	NULL
,	NULL
18-OH-RA	NULL
,	NULL
and	NULL
5,6-epoxy-RA	NULL
)	NULL
,	NULL
and	NULL
that	NULL
these	NULL
metabolites	NULL
are	NULL
active	NULL
retinoids	NULL
in	NULL
vitro	NULL
with	NULL
regard	NULL
to	NULL
cell	NULL
growth	NULL
inhibition	NULL
,	NULL
cell	NULL
cycle	NULL
arrest	NULL
in	NULL
G	NULL
,	NULL
phase	NULL
,	NULL
cell	NULL
differentiation	NULL
,	NULL
NB	NULL
reorganization	NULL
,	NULL
and	NULL
degradation	NULL
of	NULL
the	NULL
chimeric	NULL
protein	NULL
PML-RARa	NULL
«	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
when	NULL
using	NULL
a	NULL
specific	NULL
RARa	NULL
antag-onist	NULL
,	NULL
ATRA	NULL
metabolites	NULL
are	NULL
shown	NULL
to	NULL
act	NULL
via	NULL
the	NULL
RARa	NULL
nuclear	NULL
receptor	NULL
signaling	NULL
pathway	NULL
,	NULL
as	NULL
does	NULL
the	NULL
parent	NULL
compound	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Chemicals	NULL
.	NULL

ATRA	NULL
,	NULL
its	NULL
isomers	NULL
13-cis-RA	NULL
and	NULL
9-cis-RA	NULL
,	NULL
NBT	NULL
,	NULL
PMA	NULL
,	NULL
and	NULL
propidium	NULL
iodide	NULL
were	NULL
purchased	NULL
from	NULL
Sigma-Aldrich	NULL
(	NULL
St-Quentin-Fallavier	NULL
,	NULL
France	NULL
)	NULL
.	NULL

4-OH-RA	NULL
,	NULL
4-0x0-RA	NULL
,	NULL
18-OH-RA	NULL
,	NULL
and	NULL
5,6-epoxy-RA	NULL
were	NULL
kindly	NULL
donated	NULL
by	NULL
Dr.	NULL
Michael	NULL
Klaus	NULL
(	NULL
Hoffmann-La	NULL
Roche	NULL
Ltd.	NULL
,	NULL
Basel	NULL
,	NULL
Switzerland	NULL
)	NULL
and	NULL
Dr.	NULL
Louise	NULL
H.	NULL
Foley	NULL
(	NULL
Hoffmann-La	NULL
Roche	NULL
Inc.	NULL
,	NULL
Nutley	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

The	NULL
RARa	NULL
antagonist	NULL
BMS614	NULL
was	NULL
synthesized	NULL
by	NULL
Bristol-Myers	NULL
Squibb	NULL
and	NULL
kindly	NULL
donated	NULL
by	NULL
Dr.	NULL
H.	NULL
Gronemeyer	NULL
(	NULL
Institut	NULL
de	NULL
Génétique	NULL
et	NULL
de	NULL
Biologie	NULL
Molécu-laire	NULL
et	NULL
Cellulaire	NULL
,	NULL
IIlkirch	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Stock	NULL
solutions	NULL
of	NULL
retinoids	NULL
were	NULL
prepared	NULL
in	NULL
ethanol	NULL
at	NULL
10~	NULL
M	NULL
and	NULL
stored	NULL
protected	NULL
from	NULL
light	NULL
at	NULL
-20°C	NULL
.	NULL

Cell	NULL
Culture	NULL
.	NULL

The	NULL
NB4	NULL
human	NULL
APL	NULL
cell	NULL
line	NULL
,	NULL
developed	NULL
in	NULL
our	NULL
laboratory	NULL
(	NULL
38	NULL
)	NULL
,	NULL
was	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
(	NULL
Bayer	NULL
Diagnostics	NULL
,	NULL
Puteaux	NULL
,	NULL
France	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
50	NULL
units/ml	NULL
penicillin	NULL
G	NULL
,	NULL
and	NULL
50	NULL
ug/ml	NULL
streptomycin	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
cultured	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
containing	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
.	NULL

Cell	NULL
density	NULL
was	NULL
assessed	NULL
with	NULL
an	NULL
electronic	NULL
particle	NULL
counter	NULL
and	NULL
size	NULL
analyzer	NULL
(	NULL
Coulter	NULL
Electronics	NULL
,	NULL
Hialeah	NULL
,	NULL
FL	NULL
)	NULL
.	NULL

Stock	NULL
solutions	NULL
of	NULL
retinoids	NULL
(	NULL
at	NULL
10~	NULL
m	NULL
in	NULL
ethanol	NULL
)	NULL
were	NULL
further	NULL
diluted	NULL
in	NULL
culture	NULL
medium	NULL
to	NULL
the	NULL
final	NULL
concentration	NULL
indicated	NULL
in	NULL
each	NULL
experiment	NULL
.	NULL

Final	NULL
concentration	NULL
of	NULL
ethanol	NULL
in	NULL
culture	NULL
medium	NULL
did	NULL
not	NULL
exceed	NULL
0.01	NULL
%	NULL
.	NULL

Stock	NULL
solutions	NULL
of	NULL
retinoids	NULL
were	NULL
regularly	NULL
checked	NULL
for	NULL
purity	NULL
using	NULL
reversed-phase	NULL
HPLC	NULL
analysis	NULL
and	NULL
did	NULL
not	NULL
show	NULL
any	NULL
contamination	NULL
by	NULL
ATRA	NULL
.	NULL

Cell	NULL
cultures	NULL
were	NULL
diluted	NULL
with	NULL
fresh	NULL
medium	NULL
every	NULL
48	NULL
h	NULL
,	NULL
and	NULL
drug	NULL
concentrations	NULL
were	NULL
adjusted	NULL
accordingly	NULL
.	NULL

All	NULL
of	NULL
the	NULL
experimental	NULL
procedures	NULL
were	NULL
light	NULL
protected	NULL
.	NULL

ATRA	NULL
Metabolism	NULL
in	NULL
NB4	NULL
Cells	NULL
and	NULL
HPLC	NULL
.	NULL

Cells	NULL
(	NULL
10	NULL
'	NULL
)	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
in	NULL
2	NULL
ml	NULL
of	NULL
the	NULL
above	NULL
medium	NULL
with	NULL
1	NULL
um	NULL
ATRA	NULL
for	NULL
24	NULL
h.	NULL
After	NULL
acidification	NULL
(	NULL
HCI	NULL
,	NULL
1	NULL
%	NULL
)	NULL
,	NULL
cells	NULL
and	NULL
medium	NULL
were	NULL
extracted	NULL
with	NULL
ethyl	NULL
acetate	NULL
(	NULL
39	NULL
)	NULL
,	NULL
the	NULL
organic	NULL
phase	NULL
recuperated	NULL
by	NULL
centrifugation	NULL
,	NULL
and	NULL
evaporated	NULL
under	NULL
a	NULL
gentle	NULL
nitrogen	NULL
stream	NULL
.	NULL

The	NULL
dry	NULL
residue	NULL
was	NULL
reconstituted	NULL
in	NULL
100	NULL
ul	NULL
of	NULL
meth-anol	NULL
,	NULL
and	NULL
50	NULL
ul	NULL
was	NULL
injected	NULL
onto	NULL
a	NULL
HPLC	NULL
system	NULL
composed	NULL
of	NULL
a	NULL
Varian	NULL
5000	NULL
chromatograph	NULL
,	NULL
a	NULL
C	NULL
;	NULL
&	NULL
reversed-phase	NULL
column	NULL
(	NULL
Beckman	NULL
,	NULL
Ultrasphere	NULL
5	NULL
um	NULL
,	NULL
4,6	NULL
mm	NULL
X	NULL
250	NULL
mm	NULL
)	NULL
,	NULL
protected	NULL
by	NULL
a	NULL
precolumn	NULL
,	NULL
a	NULL
UV	NULL
detector	NULL
set	NULL
at	NULL
340	NULL
nm	NULL
(	NULL
Waters	NULL
484	NULL
)	NULL
,	NULL
and	NULL
a	NULL
peak	NULL
integrator	NULL
(	NULL
Varian	NULL
4400	NULL
)	NULL
.	NULL

Elution	NULL
was	NULL
accomplished	NULL
using	NULL
a	NULL
25-min	NULL
linear	NULL
gradient	NULL
starting	NULL
at	NULL
65	NULL
%	NULL
methanol/35	NULL
%	NULL
water	NULL
with	NULL
1	NULL
%	NULL
ammonium	NULL
acetate	NULL
,	NULL
and	NULL
ending	NULL
at	NULL
90	NULL
%	NULL
methanol/10	NULL
%	NULL
water	NULL
pumped	NULL
at	NULL
1	NULL
ml/min	NULL
.	NULL

NBT	NULL
Reaction	NULL
.	NULL

Cells	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
added	NULL
to	NULL
450	NULL
ul	NULL
of	NULL
1	NULL
mg/ml	NULL
NBT	NULL
solution	NULL
containing	NULL
3	NULL
X	NULL
10~	NULL
'	NULL
M	NULL
PMA	NULL
in	NULL
PBS	NULL
buffer	NULL
,	NULL
and	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
25	NULL
min	NULL
.	NULL

Cytospin	NULL
preparations	NULL
of	NULL
200	NULL
wl	NULL
of	NULL
the	NULL
cell	NULL
suspensions	NULL
(	NULL
Cytospin	NULL
;	NULL
Shandon	NULL
)	NULL
were	NULL
allowed	NULL
to	NULL
air-dry	NULL
.	NULL

The	NULL
NBT-positive	NULL
and	NULL
-negative	NULL
cells	NULL
were	NULL
scored	NULL
under	NULL
phase	NULL
contrast	NULL
microscopy	NULL
examination	NULL
(	NULL
Leica	NULL
)	NULL
at	NULL
X40	NULL
.	NULL

A	NULL
minimum	NULL
of	NULL
400	NULL
cells	NULL
per	NULL
slide	NULL
,	NULL
scored	NULL
with	NULL
at	NULL
least	NULL
two	NULL
scores	NULL
,	NULL
were	NULL
performed	NULL
per	NULL
experimental	NULL
condition	NULL
.	NULL

May-Griinwald	NULL
Giemsa	NULL
Staining	NULL
.	NULL

Cytospin	NULL
preparations	NULL
of	NULL
2	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
allowed	NULL
to	NULL
air-dry	NULL
,	NULL
incubated	NULL
in	NULL
pure	NULL
May-Griinwald	NULL
solution	NULL
for	NULL
5	NULL
min	NULL
,	NULL
then	NULL
in	NULL
50	NULL
%	NULL
May-Griinwald/water	NULL
for	NULL
10	NULL
min	NULL
,	NULL
washed	NULL
in	NULL
water	NULL
,	NULL
and	NULL
incubated	NULL
in	NULL
a	NULL
20	NULL
%	NULL
Giemsa/water	NULL
solution	NULL
for	NULL
20	NULL
min	NULL
.	NULL

The	NULL
slides	NULL
were	NULL
then	NULL
washed	NULL
in	NULL
water	NULL
,	NULL
air-dried	NULL
,	NULL
and	NULL
examined	NULL
under	NULL
immersion	NULL
microscopy	NULL
(	NULL
Leica	NULL
,	NULL
X63	NULL
)	NULL
.	NULL

Flow	NULL
Cytometry	NULL
Analysis	NULL
of	NULL
Cell	NULL
Cycle	NULL
Distribution	NULL
.	NULL

Cells	NULL
(	NULL
1	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
washed	NULL
in	NULL
PBS	NULL
and	NULL
resuspended	NULL
in	NULL
200	NULL
ul	NULL
of	NULL
PBS	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
fixed	NULL
in	NULL
2	NULL
ml	NULL
of	NULL
75	NULL
%	NULL
ethanol/water	NULL
for	NULL
2	NULL
min	NULL
,	NULL
centrifuged	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
PBS	NULL
solution	NULL
with	NULL
40	NULL
ug	NULL
of	NULL
propidium	NULL
iodide	NULL
and	NULL
100	NULL
ug	NULL
of	NULL
RNase	NULL
A	NULL
for	NULL
TOL	NULL
30	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

Propidium	NULL
iodide	NULL
(	NULL
red	NULL
)	NULL
fluorescence	NULL
was	NULL
measured	NULL
using	NULL
a	NULL
FACScan	NULL
flow	NULL
cytometer	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
with	NULL
10	NULL
%	NULL
cells	NULL
acquired	NULL
per	NULL
sample	NULL
.	NULL

Flow	NULL
Cytometry	NULL
Analysis	NULL
of	NULL
Cell	NULL
Surface	NULL
Integrin	NULL
Expression	NULL
.	NULL

Cells	NULL
(	NULL
1	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
an	NULL
anti-CD11c-PE	NULL
,	NULL
or	NULL
the	NULL
isotype	NULL
control	NULL
IgG2a-PE	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
,	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
in	NULL
the	NULL
dark	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
PBS	NULL
and	NULL
resuspended	NULL
in	NULL
500	NULL
ul	NULL
of	NULL
PBS	NULL
.	NULL

PE	NULL
(	NULL
red	NULL
)	NULL
fluorescence	NULL
was	NULL
measured	NULL
using	NULL
a	NULL
FACScan	NULL
flow	NULL
cytometer	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
with	NULL
10+	NULL
cells	NULL
acquired	NULL
per	NULL
sample	NULL
.	NULL

Immunofluorescence	NULL
.	NULL

Cytospin	NULL
preparations	NULL
of	NULL
10°	NULL
cells	NULL
were	NULL
allowed	NULL
to	NULL
air-dry	NULL
for	NULL
24	NULL
h	NULL
,	NULL
fixed	NULL
with	NULL
acetone	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
,	NULL
and	NULL
air-dried	NULL
for	NULL
20	NULL
min	NULL
.	NULL

The	NULL
slides	NULL
were	NULL
rehydrated	NULL
for	NULL
10	NULL
min	NULL
in	NULL
PBS	NULL
and	NULL
then	NULL
incubated	NULL
with	NULL
a	NULL
polyclonal	NULL
rabbit	NULL
antiserum	NULL
directed	NULL
against	NULL
a	NULL
PML	NULL
recombinant	NULL
protein	NULL
(	NULL
40	NULL
)	NULL
at	NULL
a	NULL
dilution	NULL
of	NULL
1:500	NULL
in	NULL
PBS	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
slides	NULL
were	NULL
then	NULL
incubated	NULL
with	NULL
fluorescein-coupled	NULL
antirabbit	NULL
secondary	NULL
antibody	NULL
(	NULL
Sigma	NULL
)	NULL
at	NULL
a	NULL
dilution	NULL
of	NULL
1:200	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
the	NULL
dark	NULL
.	NULL

All	NULL
of	NULL
the	NULL
incubations	NULL
were	NULL
followed	NULL
by	NULL
three	NULL
washes	NULL
in	NULL
PBS	NULL
for	NULL
5	NULL
min	NULL
.	NULL

Preparations	NULL
were	NULL
examined	NULL
under	NULL
fluorescence	NULL
microscopy	NULL
(	NULL
Leica	NULL
,	NULL
X63	NULL
)	NULL
.	NULL

Western	NULL
Blot	NULL
.	NULL

Crude	NULL
cytoplasmic	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
untreated	NULL
and	NULL
treated	NULL
NB4	NULL
cells	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
collected	NULL
,	NULL
washed	NULL
once	NULL
with	NULL
cold	NULL
PBS	NULL
,	NULL
centrifuged	NULL
at	NULL
1300	NULL
rpm	NULL
at	NULL
4°C	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
buffer	NULL
A	NULL
[	NULL
10	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
1.5	NULL
mm	NULL
MgCI12	NULL
,	NULL
10	NULL
mM	NULL
KCl	NULL
,	NULL
and	NULL
0.5	NULL
mm	NULL
DTT	NULL
]	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

After	NULL
centrifugation	NULL
for	NULL
1	NULL
min	NULL
at	NULL
5000	NULL
rpm	NULL
at	NULL
4°C	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
for	NULL
1	NULL
min	NULL
on	NULL
ice	NULL
in	NULL
buffer	NULL
A	NULL
containing	NULL
0.2	NULL
%	NULL
NP40	NULL
,	NULL
1.5	NULL
ug/ml	NULL
protease	NULL
inhibitor	NULL
cocktail	NULL
,	NULL
and	NULL
0.2	NULL
%	NULL
phenylmethylsulfony	NULL
]	NULL
fluoride	NULL
,	NULL
and	NULL
centrifuged	NULL
1	NULL
min	NULL
at	NULL
5000	NULL
rpm	NULL
.	NULL

Supernatants	NULL
corresponding	NULL
to	NULL
cytoplasmic	NULL
proteins	NULL
were	NULL
collected	NULL
,	NULL
and	NULL
the	NULL
nuclear	NULL
proteins	NULL
contained	NULL
in	NULL
the	NULL
pellets	NULL
were	NULL
extracted	NULL
with	NULL
buffer	NULL
B	NULL
[	NULL
20	NULL
mm	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mm	NULL
DTT	NULL
,	NULL
0.42	NULL
M	NULL
NaCl	NULL
,	NULL
25	NULL
%	NULL
v/v	NULL
glycerol	NULL
,	NULL
1.5	NULL
ug/ml	NULL
protease	NULL
inhibition	NULL
cocktail	NULL
,	NULL
and	NULL
0.2	NULL
mM	NULL
phenyImethylsul-fonyl	NULL
fluoride	NULL
)	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
and	NULL
centrifuged	NULL
1	NULL
min	NULL
at	NULL
5000	NULL
rpm	NULL
at	NULL
4°C	NULL
.	NULL

Cytoplasmic	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
frozen	NULL
at	NULL
-80°C	NULL
.	NULL

Nuclear	NULL
protein	NULL
extracts	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
were	NULL
boiled	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
5	NULL
%	NULL
B-mercaptoethanol	NULL
and	NULL
loaded	NULL
onto	NULL
8	NULL
%	NULL
SDS-polyacrylamide	NULL
gels	NULL
,	NULL
electrophoresed	NULL
,	NULL
and	NULL
blotted	NULL
onto	NULL
polyvinylidene	NULL
difluoride	NULL
membranes	NULL
(	NULL
Immobilon	NULL
P	NULL
;	NULL
Millipore	NULL
)	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
blocked	NULL
with	NULL
4	NULL
%	NULL
nonfat	NULL
milk	NULL
in	NULL
PBS	NULL
for	NULL
3	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
then	NULL
incubated	NULL
with	NULL
primary	NULL
human	NULL
antibody	NULL
anti-RARa	NULL
«	NULL
[	NULL
RP	NULL
&	NULL
(	NULL
F	NULL
)	NULL
;	NULL
1:5000	NULL
;	NULL
Ref	NULL
.	NULL

41	NULL
]	NULL
in	NULL
PBS-T	NULL
(	NULL
PBS	NULL
and	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
)	NULL
and	NULL
0.5	NULL
%	NULL
milk	NULL
for	NULL
18	NULL
h	NULL
at	NULL
4°C	NULL
.	NULL

Membranes	NULL
were	NULL
washed	NULL
five	NULL
times	NULL
for	NULL
5	NULL
min	NULL
each	NULL
with	NULL
PBS-T	NULL
,	NULL
incubated	NULL
with	NULL
horseradish	NULL
peroxidase-coupled	NULL
antirabbit	NULL
antibody	NULL
(	NULL
1:10000	NULL
;	NULL
Jackson	NULL
Labo-ratories	NULL
)	NULL
for	NULL
30	NULL
min	NULL
in	NULL
PBS-T	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
and	NULL
washed	NULL
five	NULL
times	NULL
for	NULL
5	NULL
min	NULL
with	NULL
PBS-T	NULL
.	NULL

Detection	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
the	NULL
ECL	NULL
kit	NULL
(	NULL
Amersham	NULL
;	NULL
Ref	NULL
.	NULL

42	NULL
)	NULL
.	NULL

Determination	NULL
of	NULL
Relative	NULL
Potency	NULL
of	NULL
the	NULL
Retinoids	NULL
.	NULL

NB4	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
cells/ml	NULL
)	NULL
were	NULL
exposed	NULL
to	NULL
ATRA	NULL
or	NULL
its	NULL
metabolites	NULL
at	NULL
concentrations	NULL
ranging	NULL
from	NULL
7	NULL
nM	NULL
to	NULL
1	NULL
M	NULL
,	NULL
the	NULL
NBT	NULL
test	NULL
was	NULL
performed	NULL
at	NULL
72	NULL
h	NULL
,	NULL
and	NULL
the	NULL
positive	NULL
cells	NULL
were	NULL
scored	NULL
as	NULL
described	NULL
above	NULL
.	NULL

The	NULL
data	NULL
from	NULL
three	NULL
separate	NULL
experiments	NULL
were	NULL
plotted	NULL
on	NULL
a	NULL
semilogarithmic	NULL
scale	NULL
to	NULL
determine	NULL
the	NULL
EC	NULL
;	NULL
,	NULL
that	NULL
elicited	NULL
half	NULL
maximal	NULL
NBT-positive	NULL
cells	NULL
.	NULL

Nonlinear	NULL
regression	NULL
analysis	NULL
was	NULL
carried	NULL
out	NULL
using	NULL
a	NULL
sigmoidal	NULL
dose-response	NULL
curve	NULL
and	NULL
GraphPad	NULL
software	NULL
.	NULL

RESULTS	NULL
ATRA	NULL
Metabolism	NULL
in	NULL
NB4	NULL
Cells	NULL
.	NULL

We	NULL
first	NULL
evaluated	NULL
the	NULL
ability	NULL
of	NULL
human	NULL
NB4	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
to	NULL
metabolize	NULL
ATRA	NULL
.	NULL

Fig	NULL
.	NULL

1	NULL
shows	NULL
the	NULL
ATRA	NULL
metabolites	NULL
formed	NULL
after	NULL
24	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
um	NULL
ATRA	NULL
.	NULL

The	NULL
metabolites	NULL
formed	NULL
were	NULL
4-0x0-RA	NULL
,	NULL
4-O0H-RA	NULL
,	NULL
18-OH-RA	NULL
,	NULL
and	NULL
5,6-epoxy-RA	NULL
,	NULL
which	NULL
presented	NULL
concentrations	NULL
of	NULL
0.06	NULL
,	NULL
0.03	NULL
,	NULL
0.08	NULL
,	NULL
and	NULL
0.39	NULL
um	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
stereoisomers	NULL
13-cis-RA	NULL
and	NULL
9-cis-RA	NULL
presented	NULL
concentrations	NULL
of	NULL
0.07	NULL
and	NULL
0.16	NULL
um	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
ATRA	NULL
of	NULL
0.19	NULL
um	NULL
.	NULL

NB4	NULL
Cell	NULL
Growth	NULL
Inhibition	NULL
and	NULL
Cell	NULL
Cycle	NULL
Arrest	NULL
by	NULL
ATRA	NULL
Metabolites	NULL
.	NULL

NB4	NULL
cell	NULL
growth	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
exogenously	NULL
added	NULL
ATRA	NULL
metabolites	NULL
was	NULL
assessed	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
1	NULL
wm	NULL
for	NULL
120	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

Compared	NULL
with	NULL
untreated	NULL
cells	NULL
,	NULL
the	NULL
growth	NULL
inhibition	NULL
was	NULL
found	NULL
to	NULL
be	NULL
similar	NULL
for	NULL
ATRA	NULL
and	NULL
the	NULL
4	NULL
metabolites	NULL
tested	NULL
,	NULL
yielding	NULL
50	NULL
%	NULL
growth	NULL
inhibition	NULL
between	NULL
72	NULL
and	NULL
96	NULL
h.	NULL
At	NULL
120	NULL
h	NULL
,	NULL
cell	NULL
growth	NULL
was	NULL
still	NULL
similar	NULL
for	NULL
all	NULL
compounds	NULL
,	NULL
and	NULL
ranged	NULL
from	NULL
22	NULL
to	NULL
31	NULL
%	NULL
of	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
2001	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

DIFFERENTIATION	NULL
OF	NULL
NB4	NULL
CELLS	NULL
BY	NULL
ATRA	NULL
METABOLITES	NULL
Absorbance	NULL
(	NULL
340	NULL
nm	NULL
)	NULL
mAU	NULL
4	NULL
8	NULL
12	NULL
16	NULL
20	NULL
-	NULL
24	NULL
-	NULL
28	NULL
Minutes	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

ATRA	NULL
metabolism	NULL
by	NULL
human	NULL
NB4	NULL
promyelocytic	NULL
cells	NULL
.	NULL

A	NULL
,	NULL
gradient	NULL
reversed-phase	NULL
HPLC	NULL
chromatogram	NULL
of	NULL
ATRA	NULL
principal	NULL
metabolites	NULL
formed	NULL
in	NULL
vitro	NULL
after	NULL
a	NULL
24-h	NULL
incubation	NULL
of	NULL
NB4	NULL
cells	NULL
with	NULL
1	NULL
um	NULL
ATRA	NULL
.	NULL

The	NULL
identified	NULL
metabolites	NULL
are	NULL
4-0x0-RA	NULL
(	NULL
peak	NULL
1	NULL
)	NULL
,	NULL
4-0H-RA	NULL
(	NULL
peak	NULL
2	NULL
)	NULL
,	NULL
18-OH-RA	NULL
(	NULL
peak	NULL
3	NULL
)	NULL
,	NULL
and	NULL
5,6-epoxy-RA	NULL
(	NULL
peak	NULL
4	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
ATRA	NULL
(	NULL
peak	NULL
7	NULL
)	NULL
,	NULL
its	NULL
stereoisomers	NULL
,	NULL
13-cis-RA	NULL
(	NULL
peak	NULL
5	NULL
)	NULL
and	NULL
9-cis-RA	NULL
(	NULL
peak	NULL
6	NULL
)	NULL
are	NULL
also	NULL
detected	NULL
.	NULL

B	NULL
,	NULL
standard	NULL
metabolites	NULL
at	NULL
1	NULL
um	NULL
:	NULL
4-0x0-RA	NULL
(	NULL
peak	NULL
1	NULL
)	NULL
,	NULL
4-0H-RA	NULL
(	NULL
peak	NULL
2	NULL
)	NULL
,	NULL
18-OH-RA	NULL
(	NULL
peak	NULL
3	NULL
)	NULL
,	NULL
5,6-epoxy-RA	NULL
(	NULL
peak	NULL
4	NULL
)	NULL
,	NULL
13-cis-RA	NULL
(	NULL
peak	NULL
5	NULL
)	NULL
,	NULL
9-cis-RA	NULL
(	NULL
peak	NULL
6	NULL
)	NULL
,	NULL
and	NULL
ATRA	NULL
(	NULL
peak	NULL
7	NULL
)	NULL
.	NULL

>	NULL
35	NULL
5,6-epoxy-RA	NULL
Cells	NULL
/	NULL
mi	NULL
(	NULL
x	NULL
10	NULL
®	NULL
)	NULL
0	NULL
-	NULL
N	NULL
o	NULL
A	NULL
o	NULL
®	NULL
~	NULL
o	NULL
©	NULL
Percent	NULL
of	NULL
cells	NULL
li	NULL
8	NULL
8	NULL
s	NULL
s	NULL
o	NULL
o	NULL
25	NULL
234	NULL
12345	NULL
1	NULL
3	NULL
125	NULL
12345	NULL
Days	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

A	NULL
,	NULL
NB4	NULL
cell	NULL
growth	NULL
inhibition	NULL
by	NULL
ATRA	NULL
metabolites	NULL
.	NULL

NB4	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
the	NULL
indicated	NULL
retinoid	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1	NULL
um	NULL
,	NULL
and	NULL
cell	NULL
density	NULL
was	NULL
assessed	NULL
using	NULL
an	NULL
electronic	NULL
particle	NULL
counter	NULL
.	NULL

Mean	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
;	NULL
error	NULL
bars	NULL
,	NULL
SD	NULL
.	NULL

B	NULL
,	NULL
ATRA	NULL
metabolite	NULL
effect	NULL
on	NULL
NB4	NULL
cell	NULL
cycle	NULL
distribution	NULL
.	NULL

NB4	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
1	NULL
um	NULL
retinoids	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
and	NULL
then	NULL
stained	NULL
with	NULL
propidium	NULL
iodide	NULL
.	NULL

Cells	NULL
(	NULL
10	NULL
%	NULL
)	NULL
were	NULL
analyzed	NULL
for	NULL
each	NULL
point	NULL
using	NULL
a	NULL
FACScan	NULL
flow	NULL
cytometer	NULL
.	NULL

untreated	NULL
cells	NULL
.	NULL

Cell	NULL
growth	NULL
declined	NULL
to	NULL
11-13	NULL
%	NULL
of	NULL
controls	NULL
for	NULL
ATRA	NULL
and	NULL
its	NULL
metabolites	NULL
at	NULL
168	NULL
h	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
parallel	NULL
experiments	NULL
,	NULL
the	NULL
influence	NULL
of	NULL
ATRA	NULL
or	NULL
its	NULL
metabolites	NULL
on	NULL
the	NULL
cell	NULL
cycle	NULL
distribution	NULL
was	NULL
assessed	NULL
for	NULL
5	NULL
days	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

A	NULL
time-dependent	NULL
cell	NULL
cycle	NULL
accumulation	NULL
in	NULL
the	NULL
G	NULL
,	NULL
phase	NULL
was	NULL
observed	NULL
for	NULL
all	NULL
compounds	NULL
tested	NULL
,	NULL
yielding	NULL
82-84	NULL
%	NULL
G	NULL
,	NULL
accumulation	NULL
at	NULL
day	NULL
5	NULL
,	NULL
at	NULL
the	NULL
expense	NULL
of	NULL
the	NULL
S	NULL
and	NULL
G	NULL
,	NULL
-M	NULL
phases	NULL
.	NULL

These	NULL
data	NULL
are	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
observed	NULL
growth	NULL
arrest	NULL
.	NULL

NB4	NULL
Cell	NULL
Differentiation	NULL
by	NULL
ATRA	NULL
Metabolites	NULL
.	NULL

Because	NULL
the	NULL
ATRA	NULL
metabolites	NULL
appeared	NULL
to	NULL
be	NULL
as	NULL
effective	NULL
as	NULL
the	NULL
parent	NULL
compound	NULL
with	NULL
regard	NULL
to	NULL
cell	NULL
growth	NULL
inhibition	NULL
and	NULL
cell	NULL
cycle	NULL
arrest	NULL
,	NULL
we	NULL
assessed	NULL
the	NULL
differentiating	NULL
potential	NULL
of	NULL
these	NULL
retinoids	NULL
in	NULL
NB4	NULL
cells	NULL
using	NULL
cell	NULL
morphology	NULL
,	NULL
NBT	NULL
reduction	NULL
,	NULL
and	NULL
CD11¢	NULL
expression	NULL
.	NULL

Morphological	NULL
differentiation	NULL
using	NULL
May-Griinwald	NULL
Giemsa	NULL
staining	NULL
of	NULL
NB4	NULL
cells	NULL
exposed	NULL
to	NULL
either	NULL
ATRA	NULL
or	NULL
its	NULL
metabolites	NULL
was	NULL
carried	NULL
out	NULL
every	NULL
day	NULL
for	NULL
5	NULL
days	NULL
.	NULL

The	NULL
first	NULL
signs	NULL
of	NULL
morphological	NULL
differentiation	NULL
were	NULL
observed	NULL
at	NULL
72	NULL
h	NULL
for	NULL
all	NULL
compounds	NULL
,	NULL
and	NULL
the	NULL
differentiation	NULL
was	NULL
more	NULL
pronounced	NULL
for	NULL
18-OH-RA	NULL
and	NULL
5,6-epoxy-RA	NULL
than	NULL
for	NULL
ATRA	NULL
,	NULL
4-0xo-RA	NULL
or	NULL
4-OH-RA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

At	NULL
96	NULL
h	NULL
,	NULL
the	NULL
granulocytic	NULL
maturation	NULL
pattern	NULL
was	NULL
similar	NULL
for	NULL
all	NULL
retinoids	NULL
,	NULL
with	NULL
polylobular	NULL
nuclei	NULL
,	NULL
decreased	NULL
nuclear	NULL
:	NULL
cytoplasmic	NULL
ratio	NULL
,	NULL
and	NULL
decreased	NULL
cytoplasm	NULL
staining	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

ATRA	NULL
and	NULL
its	NULL
metabolites	NULL
induced	NULL
similar	NULL
kinetics	NULL
of	NULL
differentiation	NULL
with	NULL
comparable	NULL
efficacy	NULL
at	NULL
1	NULL
um	NULL
reaching	NULL
82-88	NULL
%	NULL
A	NULL
o_o	NULL
``	NULL
OQQ	NULL
control	NULL
g	NULL
A	NULL
18-OH-RA	NULL
1	NULL
Ko	NULL
8	NULL
c	NULL
¢	NULL
o	NULL
g	NULL
:	NULL
{	NULL
i	NULL
hl	NULL
€	NULL
C	NULL
J	NULL
¢	NULL
r	NULL
RH	NULL
§	NULL
:	NULL
H	NULL
8	NULL
§	NULL
:	NULL
A	NULL
(	NULL
H	NULL
a	NULL
F	NULL
§	NULL
:	NULL
$	NULL
k	NULL
&	NULL
:	NULL
§	NULL
H	NULL
m	NULL
NF	NULL
“	NULL
Q	NULL
.	NULL

NH	NULL
>	NULL
RF	NULL
§	NULL
:	NULL
T	NULL
*	NULL
§	NULL
§	NULL
:	NULL
§	NULL
o	NULL
§	NULL
J	NULL
||	NULL
°	NULL
&	NULL
i	NULL
§	NULL
:	NULL
§	NULL
:	NULL
O	NULL
Counts	NULL
CD11-c-PE	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Differentiation	NULL
induction	NULL
of	NULL
NB4	NULL
cells	NULL
by	NULL
ATRA	NULL
metabolites	NULL
.	NULL

A	NULL
,	NULL
May-Griinwald	NULL
Giemsa	NULL
staining	NULL
of	NULL
NB4	NULL
cells	NULL
.	NULL

NB4	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
1	NULL
uM	NULL
ATRA	NULL
or	NULL
its	NULL
metabolites	NULL
for	NULL
96	NULL
h	NULL
and	NULL
stained	NULL
with	NULL
May-Griinwald	NULL
Giemsa	NULL
(	NULL
X	NULL
63	NULL
)	NULL
.	NULL

B	NULL
,	NULL
NBT	NULL
assay	NULL
of	NULL
NB4	NULL
cells	NULL
.	NULL

The	NULL
reduction	NULL
of	NULL
NBT	NULL
by	NULL
NB4	NULL
cells	NULL
treated	NULL
with	NULL
1	NULL
um	NULL
ATRA	NULL
or	NULL
its	NULL
metabolites	NULL
was	NULL
determined	NULL
every	NULL
day	NULL
for	NULL
5	NULL
days	NULL
.	NULL

A	NULL
minimum	NULL
of	NULL
400	NULL
cells	NULL
per	NULL
slide	NULL
were	NULL
scored	NULL
,	NULL
and	NULL
at	NULL
least	NULL
two	NULL
scores	NULL
were	NULL
performed	NULL
per	NULL
experimental	NULL
condition	NULL
.	NULL

C	NULL
,	NULL
CD11c	NULL
cell	NULL
surface	NULL
marker	NULL
expression	NULL
in	NULL
NB4	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
exposed	NULL
to	NULL
1	NULL
um	NULL
concentration	NULL
of	NULL
the	NULL
indicated	NULL
retinoid	NULL
for	NULL
24	NULL
h	NULL
and	NULL
incubated	NULL
with	NULL
an	NULL
anti-CD11c-PE	NULL
or	NULL
with	NULL
the	NULL
isotype	NULL
control	NULL
IgG2a-PE	NULL
.	NULL

Cells	NULL
(	NULL
10°	NULL
)	NULL
were	NULL
analyzed	NULL
for	NULL
each	NULL
point	NULL
using	NULL
a	NULL
FACScan	NULL
flow	NULL
cytometer	NULL
.	NULL

702	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
2001	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

DIFFERENTIATION	NULL
OF	NULL
NB4	NULL
CELLS	NULL
BY	NULL
ATRA	NULL
METABOLITES	NULL
Table	NULL
1	NULL
CD11¢	NULL
integrin	NULL
cell	NULL
surface	NULL
expression	NULL
of	NULL
NB4	NULL
cells	NULL
exposed	NULL
to	NULL
ATRA	NULL
or	NULL
its	NULL
metabolites	NULL
``	NULL
%	NULL
CD11c	NULL
positive	NULL
cells	NULL
Treatment	NULL
``	NULL
24	NULL
h	NULL
48	NULL
h	NULL
72	NULL
h	NULL
ATRA	NULL
67	NULL
79	NULL
70	NULL
4-0	NULL
%	NULL
0-RA	NULL
53	NULL
61	NULL
51	NULL
4-OH-RA	NULL
63	NULL
79	NULL
75	NULL
18-OH-RA	NULL
62	NULL
67	NULL
65	NULL
5,6-epoxy-RA	NULL
67	NULL
81	NULL
76	NULL
``	NULL
The	NULL
CD11c-labeled	NULL
controls	NULL
and	NULL
the	NULL
isotype	NULL
(	NULL
IgG2a	NULL
)	NULL
control	NULL
cells	NULL
showed	NULL
1	NULL
%	NULL
positive	NULL
cells	NULL
.	NULL

*	NULL
Cells	NULL
were	NULL
exposed	NULL
to	NULL
retinoid	NULL
concentrations	NULL
of	NULL
1	NULL
um	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
.	NULL

NBT	NULL
positive	NULL
cells	NULL
in	NULL
5	NULL
days	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
ATRA	NULL
and	NULL
its	NULL
metabolites	NULL
induced	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
maturation-specific	NULL
cell	NULL
surface	NULL
marker	NULL
CD11¢	NULL
in	NULL
NB4	NULL
cells	NULL
24	NULL
h	NULL
after	NULL
retinoid	NULL
exposure	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
;	NULL
at	NULL
48	NULL
or	NULL
72	NULL
h	NULL
,	NULL
there	NULL
was	NULL
little	NULL
change	NULL
in	NULL
the	NULL
percentage	NULL
of	NULL
CD11c	NULL
positive	NULL
cells	NULL
compared	NULL
with	NULL
that	NULL
at	NULL
24	NULL
h	NULL
,	NULL
and	NULL
no	NULL
difference	NULL
was	NULL
noted	NULL
between	NULL
ATRA	NULL
and	NULL
its	NULL
metabolites	NULL
with	NULL
regard	NULL
to	NULL
the	NULL
level	NULL
of	NULL
CD11¢	NULL
expression	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

NB	NULL
Reorganization	NULL
and	NULL
PML-RARa	NULL
«	NULL
Protein	NULL
Degradation	NULL
by	NULL
ATRA	NULL
Metabolites	NULL
.	NULL

The	NULL
intracellular	NULL
distribution	NULL
of	NULL
PML	NULL
and	NULL
PML-RARa	NULL
proteins	NULL
in	NULL
NB4	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
exposed	NULL
to	NULL
ATRA	NULL
or	NULL
its	NULL
four	NULL
metabolites	NULL
at	NULL
1	NULL
um	NULL
for	NULL
5	NULL
days	NULL
was	NULL
analyzed	NULL
by	NULL
immunocytochemistry	NULL
.	NULL

The	NULL
nuclei	NULL
from	NULL
control	NULL
cells	NULL
presented	NULL
fine	NULL
and	NULL
numerous	NULL
labeled	NULL
dots	NULL
containing	NULL
PML	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
micropunctated	NULL
NBs	NULL
typically	NULL
found	NULL
in	NULL
APL	NULL
cells	NULL
.	NULL

When	NULL
the	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
ATRA	NULL
,	NULL
the	NULL
morphological	NULL
reorganization	NULL
was	NULL
characterized	NULL
by	NULL
an	NULL
increase	NULL
in	NULL
NB	NULL
size	NULL
corresponding	NULL
to	NULL
macropunctated	NULL
NBs	NULL
,	NULL
and	NULL
a	NULL
decrease	NULL
in	NULL
their	NULL
number	NULL
.	NULL

A	NULL
similar	NULL
pattern	NULL
of	NULL
NB	NULL
reorganization	NULL
to	NULL
that	NULL
seen	NULL
with	NULL
ATRA	NULL
was	NULL
observed	NULL
for	NULL
all	NULL
of	NULL
the	NULL
metabolites	NULL
tested	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

As	NULL
early	NULL
as	NULL
24	NULL
h	NULL
,	NULL
NB	NULL
reorganization	NULL
could	NULL
be	NULL
seen	NULL
,	NULL
which	NULL
reached	NULL
a	NULL
maximum	NULL
at	NULL
72	NULL
h.	NULL
No	NULL
major	NULL
difference	NULL
in	NULL
NB	NULL
size	NULL
was	NULL
observed	NULL
between	NULL
72	NULL
h	NULL
and	NULL
120	NULL
h	NULL
for	NULL
ATRA	NULL
or	NULL
its	NULL
metabolites	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Concomitant	NULL
to	NULL
NB	NULL
reorganization	NULL
,	NULL
degradation	NULL
of	NULL
the	NULL
PML-RARa	NULL
chimeric	NULL
protein	NULL
by	NULL
ATRA	NULL
metabolites	NULL
was	NULL
also	NULL
assessed	NULL
.	NULL

ATRA	NULL
metabolites	NULL
treatment	NULL
induced	NULL
PML-RARa	NULL
degradation	NULL
as	NULL
did	NULL
ATRA	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

The	NULL
protein	NULL
became	NULL
barely	NULL
detectable	NULL
at	NULL
48	NULL
h	NULL
,	NULL
with	NULL
the	NULL
emergence	NULL
of	NULL
a	NULL
lower	NULL
molecular	NULL
weight	NULL
band	NULL
corresponding	NULL
to	NULL
degradation	NULL
of	NULL
the	NULL
chimeric	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Determination	NULL
of	NULL
the	NULL
Relative	NULL
Potency	NULL
of	NULL
ATRA	NULL
and	NULL
Its	NULL
Metabolites	NULL
.	NULL

NB4	NULL
cells	NULL
were	NULL
treated	NULL
by	NULL
ATRA	NULL
or	NULL
its	NULL
metabolites	NULL
at	NULL
concentrations	NULL
ranging	NULL
from	NULL
7	NULL
nm	NULL
to	NULL
1	NULL
um	NULL
for	NULL
72	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

ATRA	NULL
was	NULL
more	NULL
efficient	NULL
than	NULL
its	NULL
four	NULL
metabolites	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
differentiation	NULL
,	NULL
with	NULL
effective	NULL
concentrations	NULL
to	NULL
elicit	NULL
50	NULL
%	NULL
(	NULL
EC	NULL
,	NULL
)	NULL
of	NULL
NBT	NULL
positive	NULL
cells	NULL
of	NULL
15.8	NULL
+	NULL
1.7	NULL
nm	NULL
.	NULL

The	NULL
metabolites	NULL
yielded	NULL
ECs	NULL
,	NULL
values	NULL
of	NULL
38.3	NULL
+	NULL
1.3	NULL
nm	NULL
for	NULL
4-0x0-RA	NULL
,	NULL
55.5	NULL
+	NULL
1.8	NULL
nm	NULL
for	NULL
18-OH-RA	NULL
,	NULL
79.8	NULL
+	NULL
1.8	NULL
nm	NULL
for	NULL
4-OH-RA	NULL
,	NULL
and	NULL
99.5	NULL
+	NULL
1.5	NULL
nm	NULL
for	NULL
5,6-epoxy-RA	NULL
.	NULL

However	NULL
,	NULL
at	NULL
higher	NULL
concentrations	NULL
(	NULL
from	NULL
0.25	NULL
to	NULL
1	NULL
um	NULL
)	NULL
,	NULL
ATRA	NULL
and	NULL
its	NULL
metabolites	NULL
showed	NULL
similar	NULL
differentiation	NULL
efficiency	NULL
of	NULL
about	NULL
80	NULL
%	NULL
NBT	NULL
positive	NULL
cells	NULL
.	NULL

Effect	NULL
of	NULL
RARa	NULL
Antagonist	NULL
on	NULL
the	NULL
Induction	NULL
of	NULL
Differentiation	NULL
by	NULL
ATRA	NULL
Metabolites	NULL
.	NULL

Because	NULL
the	NULL
ATRA	NULL
metabolites	NULL
could	NULL
induce	NULL
NB4	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
differentiation	NULL
,	NULL
it	NULL
was	NULL
of	NULL
interest	NULL
to	NULL
investigate	NULL
the	NULL
nuclear	NULL
receptor	NULL
pathways	NULL
involved	NULL
in	NULL
this	NULL
response	NULL
.	NULL

Because	NULL
differentiation	NULL
of	NULL
NB4	NULL
cells	NULL
by	NULL
ATRA	NULL
is	NULL
mediated	NULL
through	NULL
the	NULL
RARa	NULL
receptor	NULL
,	NULL
we	NULL
therefore	NULL
blocked	NULL
this	NULL
pathway	NULL
using	NULL
the	NULL
RARa-specific	NULL
antagonist	NULL
BMS614	NULL
.	NULL

NB4	NULL
cells	NULL
were	NULL
simultaneously	NULL
treated	NULL
with	NULL
ATRA	NULL
or	NULL
its	NULL
metabolites	NULL
at	NULL
0.1	NULL
um	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
the	NULL
RARa-specific	NULL
antagonist	NULL
BMS614	NULL
(	NULL
1	NULL
um	NULL
)	NULL
for	NULL
48	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
BMS614	NULL
abolished	NULL
ATRA-induced	NULL
CD11c	NULL
expression	NULL
as	NULL
shown	NULL
by	NULL
the	NULL
decrease	NULL
in	NULL
fluorescence	NULL
intensity	NULL
to	NULL
near	NULL
control	NULL
values	NULL
.	NULL

Likewise	NULL
,	NULL
induction	NULL
of	NULL
CD11c	NULL
expression	NULL
by	NULL
the	NULL
703	NULL
ATRA	NULL
metabolites	NULL
was	NULL
blocked	NULL
by	NULL
BMS614	NULL
,	NULL
which	NULL
indicated	NULL
that	NULL
the	NULL
metabolites	NULL
induced	NULL
maturation	NULL
through	NULL
the	NULL
RARa	NULL
«	NULL
signaling	NULL
pathway	NULL
,	NULL
as	NULL
does	NULL
the	NULL
parent	NULL
compound	NULL
.	NULL

DISCUSSION	NULL
Although	NULL
ATRA	NULL
is	NULL
considered	NULL
to	NULL
be	NULL
the	NULL
best	NULL
single	NULL
agent	NULL
available	NULL
for	NULL
APL	NULL
therapy	NULL
,	NULL
it	NULL
is	NULL
limited	NULL
in	NULL
that	NULL
clinical	NULL
resistance	NULL
can	NULL
develop	NULL
A	NULL
4	NULL
PML-RARa	NULL
wee	NULL
woe	NULL
€	NULL
A~PML-RARO	NULL
or	NULL
®	NULL
``	NULL
gp	NULL
©	NULL
_	NULL
04	NULL
e	NULL
co	NULL
``	NULL
«	NULL
305.33	NULL
4	NULL
%	NULL
PML-RARa	NULL
:	NULL
wap	NULL
4	NULL
APML-RARC	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

A	NULL
,	NULL
NB	NULL
reorganization	NULL
by	NULL
ATRA	NULL
and	NULL
its	NULL
metabolites	NULL
.	NULL

Intracellular	NULL
distribution	NULL
of	NULL
PML	NULL
and	NULL
PML-RARa	NULL
proteins	NULL
in	NULL
NB4	NULL
cells	NULL
exposed	NULL
to	NULL
1	NULL
um	NULL
ATRA	NULL
or	NULL
its	NULL
4	NULL
metabolites	NULL
for	NULL
72	NULL
h	NULL
was	NULL
analyzed	NULL
by	NULL
immunocytochemistry	NULL
and	NULL
fluorescence	NULL
microscopy	NULL
(	NULL
X	NULL
63	NULL
)	NULL
.	NULL

The	NULL
slides	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
polyclonal	NULL
rabbit	NULL
antiserum	NULL
directed	NULL
against	NULL
recombinant	NULL
PML	NULL
and	NULL
then	NULL
were	NULL
incubated	NULL
with	NULL
fluorescein-coupled	NULL
antirabbit	NULL
secondary	NULL
antibody	NULL
.	NULL

Preparations	NULL
were	NULL
examined	NULL
by	NULL
fluorescence	NULL
microscopy	NULL
.	NULL

B	NULL
,	NULL
PML-RARa	NULL
chimeric	NULL
protein	NULL
degradation	NULL
by	NULL
ATRA	NULL
and	NULL
its	NULL
metabolites	NULL
.	NULL

Western	NULL
blot	NULL
of	NULL
crude	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
NB4	NULL
cells	NULL
after	NULL
a	NULL
48-h	NULL
treatment	NULL
with	NULL
1-unm	NULL
concentrations	NULL
of	NULL
the	NULL
indicated	NULL
retinoids	NULL
.	NULL

After	NULL
electrophoretic	NULL
separation	NULL
and	NULL
membrane	NULL
transfer	NULL
,	NULL
the	NULL
membranes	NULL
were	NULL
incubated	NULL
with	NULL
primary	NULL
human	NULL
antibody	NULL
anti-RARa	NULL
@	NULL
.	NULL

_	NULL
O	NULL
O	NULL
~	NULL
on	NULL
1	NULL
25	NULL
NBT	NULL
POSITIVE	NULL
CELLS	NULL
(	NULL
%	NULL
)	NULL
oa	NULL
in	NULL
5,6-epoxy-RA	NULL
0.01	NULL
0.1	NULL
1	NULL
RETINOID	NULL
CONCENTRATION	NULL
(	NULL
aM	NULL
)	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Determination	NULL
of	NULL
the	NULL
relative	NULL
potency	NULL
of	NULL
ATRA	NULL
and	NULL
its	NULL
metabolites	NULL
.	NULL

NB4	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
ATRA	NULL
or	NULL
its	NULL
metabolites	NULL
at	NULL
concentrations	NULL
ranging	NULL
from	NULL
7	NULL
nm	NULL
to	NULL
1	NULL
pM	NULL
;	NULL
the	NULL
NBT	NULL
reduction	NULL
test	NULL
was	NULL
performed	NULL
after	NULL
72	NULL
h	NULL
,	NULL
and	NULL
positive	NULL
cells	NULL
were	NULL
counted	NULL
.	NULL

Values	NULL
are	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
separate	NULL
experiments	NULL
;	NULL
error	NULL
bars	NULL
have	NULL
not	NULL
been	NULL
shown	NULL
for	NULL
legibility	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
2001	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

DIFFERENTIATION	NULL
OF	NULL
NB4	NULL
CELLS	NULL
BY	NULL
ATRA	NULL
METABOLITES	NULL
10	NULL
m	NULL
&	NULL
2	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Effect	NULL
of	NULL
the	NULL
RARa-specific	NULL
antagonist	NULL
g	NULL
BMS614	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
NB4	NULL
cell	NULL
differentia-	NULL
o	NULL
tion	NULL
by	NULL
ATRA	NULL
metabolites	NULL
.	NULL

NB4	NULL
cells	NULL
were	NULL
simul-	NULL
E	NULL
tancously	NULL
treated	NULL
with	NULL
0.1	NULL
um	NULL
ATRA	NULL
or	NULL
its	NULL
metab-	NULL
'	NULL
%	NULL
olites	NULL
and	NULL
1	NULL
pm	NULL
of	NULL
the	NULL
RARa	NULL
antagonist	NULL
BMS614	NULL
8	NULL
for	NULL
48	NULL
h.	NULL
CD11¢	NULL
expression	NULL
was	NULL
analyzed	NULL
by	NULL
flow	NULL
o	NULL
cytometry	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

T-a	NULL
,	NULL
untreated	NULL
control	NULL
cells	NULL
;	NULL
b	NULL
,	NULL
untreated	NULL
cells	NULL
stained	NULL
Q	NULL
with	NULL
anti-CD11c-PE	NULL
;	NULL
c	NULL
,	NULL
untreated	NULL
cells	NULL
stained	NULL
with	NULL
O	NULL
isotype	NULL
control	NULL
IgG2a-PE	NULL
;	NULL
d	NULL
,	NULL
cells	NULL
treated	NULL
with	NULL
BMS614	NULL
and	NULL
stained	NULL
with	NULL
CD11c-PE	NULL
.	NULL

Controls	NULL
rapidly	NULL
(	NULL
20	NULL
)	NULL
.	NULL

One	NULL
cause	NULL
of	NULL
ATRA	NULL
resistance	NULL
is	NULL
attributable	NULL
to	NULL
its	NULL
increased	NULL
metabolism	NULL
with	NULL
rapid	NULL
clearance	NULL
often	NULL
observed	NULL
in	NULL
relapsing	NULL
patients	NULL
(	NULL
43	NULL
)	NULL
.	NULL

ATRA	NULL
has	NULL
,	NULL
therefore	NULL
,	NULL
been	NULL
considered	NULL
to	NULL
be	NULL
the	NULL
unique	NULL
effective	NULL
compound	NULL
,	NULL
and	NULL
its	NULL
metabolites	NULL
have	NULL
been	NULL
considered	NULL
as	NULL
catabolic	NULL
products	NULL
.	NULL

However	NULL
,	NULL
several	NULL
authors	NULL
have	NULL
proposed	NULL
that	NULL
ATRA	NULL
metabolism	NULL
may	NULL
be	NULL
required	NULL
for	NULL
cell	NULL
growth	NULL
inhibition	NULL
of	NULL
various	NULL
cancer	NULL
cell	NULL
lines	NULL
in	NULL
vitro	NULL
,	NULL
although	NULL
no	NULL
causal	NULL
relationship	NULL
has	NULL
been	NULL
shown	NULL
(	NULL
35	NULL
,	NULL
37	NULL
,	NULL
44	NULL
)	NULL
.	NULL

Because	NULL
very	NULL
little	NULL
information	NULL
is	NULL
presently	NULL
available	NULL
concerning	NULL
the	NULL
biological	NULL
activity	NULL
of	NULL
the	NULL
principal	NULL
Phase	NULL
I	NULL
ATRA	NULL
metabolites	NULL
,	NULL
the	NULL
purpose	NULL
of	NULL
this	NULL
work	NULL
was	NULL
to	NULL
evaluate	NULL
the	NULL
in	NULL
vitro	NULL
effects	NULL
of	NULL
the	NULL
main	NULL
oxidized	NULL
metabolites	NULL
of	NULL
ATRA	NULL
using	NULL
the	NULL
NB4	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
38	NULL
)	NULL
.	NULL

The	NULL
NB4	NULL
cell	NULL
line	NULL
is	NULL
a	NULL
relevant	NULL
model	NULL
for	NULL
this	NULL
study	NULL
in	NULL
that	NULL
it	NULL
exhibits	NULL
the	NULL
chromosomal	NULL
translocation	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
specific	NULL
for	NULL
APL	NULL
,	NULL
with	NULL
the	NULL
resultant	NULL
production	NULL
of	NULL
the	NULL
chimeric	NULL
protein	NULL
PML-RARa	NULL
«	NULL
.	NULL

It	NULL
can	NULL
be	NULL
differentiated	NULL
by	NULL
ATRA	NULL
treatment	NULL
and	NULL
may	NULL
be	NULL
used	NULL
to	NULL
elucidate	NULL
mechanisms	NULL
of	NULL
differentiation	NULL
in	NULL
APL	NULL
,	NULL
a	NULL
paradigm	NULL
of	NULL
a	NULL
disease	NULL
sensitive	NULL
to	NULL
differentiation	NULL
therapy	NULL
.	NULL

Our	NULL
results	NULL
show	NULL
that	NULL
NB4	NULL
cells	NULL
metabolize	NULL
ATRA	NULL
to	NULL
the	NULL
more	NULL
polar	NULL
metabolites	NULL
4-0x0-RA	NULL
,	NULL
4-OH-RA	NULL
,	NULL
18-OH-RA	NULL
,	NULL
and	NULL
5,6-epoxy-RA	NULL
.	NULL

ATRA	NULL
metabolism	NULL
is	NULL
cytochrome	NULL
P450-dependent	NULL
and	NULL
appears	NULL
to	NULL
involve	NULL
several	NULL
isoforms	NULL
including	NULL
CYP2C8	NULL
(	NULL
45	NULL
)	NULL
and	NULL
CYP26	NULL
(	NULL
46	NULL
,	NULL
47	NULL
;	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

48	NULL
)	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
Marill	NULL
et	NULL
al	NULL
.	NULL

(	NULL
49	NULL
)	NULL
have	NULL
identified	NULL
several	NULL
other	NULL
human	NULL
cytochrome	NULL
P450s	NULL
significantly	NULL
involved	NULL
in	NULL
the	NULL
metabolism	NULL
of	NULL
ATRA	NULL
.	NULL

ATRA	NULL
and	NULL
its	NULL
metabolites	NULL
were	NULL
found	NULL
to	NULL
be	NULL
equally	NULL
active	NULL
in	NULL
terms	NULL
of	NULL
growth	NULL
inhibition	NULL
of	NULL
NB4	NULL
leukemia	NULL
cells	NULL
at	NULL
1-um	NULL
concentration	NULL
.	NULL

These	NULL
data	NULL
are	NULL
in	NULL
agreement	NULL
with	NULL
those	NULL
of	NULL
van	NULL
der	NULL
Leede	NULL
et	NULL
al	NULL
.	NULL

(	NULL
35	NULL
)	NULL
and	NULL
van	NULL
Heusden	NULL
et	NULL
al	NULL
.	NULL

(	NULL
33	NULL
)	NULL
,	NULL
who	NULL
also	NULL
observed	NULL
growth	NULL
inhibition	NULL
of	NULL
breast	NULL
cancer	NULL
cell	NULL
lines	NULL
with	NULL
ATRA	NULL
metabolites	NULL
(	NULL
4-0xo-RA	NULL
,	NULL
4-0H-RA	NULL
,	NULL
and	NULL
5,6-epoxy-RA	NULL
)	NULL
.	NULL

Rat	NULL
rhabdomyosarcoma	NULL
cells	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
sensitive	NULL
to	NULL
growth	NULL
inhibition	NULL
by	NULL
4-0x0-RA	NULL
,	NULL
4-OH-RA	NULL
,	NULL
and	NULL
5,6-epoxy-RA	NULL
(	NULL
34	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
NB4	NULL
leukemia	NULL
cell	NULL
line	NULL
used	NULL
in	NULL
this	NULL
report	NULL
appears	NULL
to	NULL
be	NULL
more	NULL
sensitive	NULL
than	NULL
solid	NULL
tumor	NULL
cell	NULL
lines	NULL
,	NULL
because	NULL
~90	NULL
%	NULL
growth	NULL
inhibition	NULL
was	NULL
obtained	NULL
in	NULL
these	NULL
cells	NULL
compared	NULL
with	NULL
40-50	NULL
%	NULL
reported	NULL
in	NULL
MCF-7	NULL
cells	NULL
or	NULL
rhabdomyosarcoma	NULL
cells	NULL
(	NULL
33-35	NULL
)	NULL
.	NULL

To	NULL
our	NULL
knowledge	NULL
,	NULL
this	NULL
is	NULL
the	NULL
first	NULL
report	NULL
on	NULL
the	NULL
growth	NULL
inhibitory	NULL
activity	NULL
of	NULL
the	NULL
principal	NULL
Phase	NULL
1	NULL
metabolites	NULL
of	NULL
ATRA	NULL
in	NULL
a	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
and	NULL
,	NULL
also	NULL
,	NULL
the	NULL
first	NULL
account	NULL
of	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
18-OH-RA	NULL
.	NULL

The	NULL
ATRA	NULL
metabolites	NULL
were	NULL
also	NULL
shown	NULL
to	NULL
be	NULL
active	NULL
in	NULL
regard	NULL
to	NULL
differentiation	NULL
induction	NULL
in	NULL
the	NULL
NB4	NULL
cells	NULL
as	NULL
evaluated	NULL
by	NULL
several	NULL
criteria	NULL
including	NULL
cell	NULL
morphology	NULL
,	NULL
NBT	NULL
reduction	NULL
test	NULL
,	NULL
and	NULL
CD11c	NULL
integrin	NULL
expression	NULL
.	NULL

These	NULL
metabolites	NULL
were	NULL
as	NULL
active	NULL
as	NULL
the	NULL
parent	NULL
compound	NULL
at	NULL
concentrations	NULL
between	NULL
0.2	NULL
and	NULL
1	NULL
um	NULL
.	NULL

At	NULL
lower	NULL
concen-trations	NULL
,	NULL
differences	NULL
were	NULL
seen	NULL
between	NULL
ATRA	NULL
and	NULL
its	NULL
metabolites	NULL
in	NULL
their	NULL
relative	NULL
potency	NULL
(	NULL
ECs	NULL
,	NULL
,	NULL
)	NULL
to	NULL
induce	NULL
maturation	NULL
of	NULL
NB4	NULL
cells	NULL
in	NULL
the	NULL
NBT	NULL
reduction	NULL
test	NULL
.	NULL

Although	NULL
ATRA	NULL
was	NULL
found	NULL
to	NULL
be	NULL
the	NULL
most	NULL
potent	NULL
retinoid	NULL
tested	NULL
(	NULL
EC	NULL
;	NULL
,	NULL
15.8	NULL
nm	NULL
)	NULL
,	NULL
4-0x0-RA	NULL
(	NULL
ECs	NULL
,	NULL
38.3	NULL
nM	NULL
)	NULL
is	NULL
also	NULL
very	NULL
9	NULL
pz	NULL
a	NULL
A	NULL
®	NULL
o	NULL
¢	NULL
S	NULL
3	NULL
P	NULL
B	NULL
O	NULL
a	NULL
.	NULL

A	NULL
E	NULL
#	NULL
a	NULL
0	NULL
-	NULL
``	NULL
+0	NULL
``	NULL
BMS614	NULL
ATRA	NULL
co	NULL
``	NULL
ae	NULL
$	NULL
o*	NULL
active	NULL
,	NULL
inasmuch	NULL
as	NULL
only	NULL
a	NULL
2.4-fold	NULL
difference	NULL
was	NULL
observed	NULL
between	NULL
this	NULL
metabolite	NULL
and	NULL
the	NULL
parent	NULL
compound	NULL
.	NULL

It	NULL
is	NULL
of	NULL
interest	NULL
to	NULL
note	NULL
that	NULL
the	NULL
EC	NULL
;	NULL
,	NULL
found	NULL
for	NULL
4-0x0-RA	NULL
is	NULL
achievable	NULL
in	NULL
vivo	NULL
in	NULL
humans	NULL
after	NULL
ATRA	NULL
administration	NULL
,	NULL
because	NULL
concentrations	NULL
in	NULL
the	NULL
range	NULL
of	NULL
19-30	NULL
ng/ml	NULL
(	NULL
61-96	NULL
nm	NULL
)	NULL
can	NULL
be	NULL
reached	NULL
(	NULL
50	NULL
)	NULL
.	NULL

In	NULL
some	NULL
studies	NULL
,	NULL
4-0x0-RA	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
more	NULL
active	NULL
than	NULL
ATRA	NULL
in	NULL
the	NULL
modulation	NULL
of	NULL
positional	NULL
specification	NULL
in	NULL
Xenopus	NULL
laevis	NULL
embryos	NULL
(	NULL
31	NULL
)	NULL
.	NULL

With	NULL
regard	NULL
to	NULL
the	NULL
EC	NULL
,	NULL
,	NULL
found	NULL
for	NULL
4-0x0-RA	NULL
,	NULL
4-O0H-RA	NULL
,	NULL
and	NULL
5,6-epoxy-RA	NULL
,	NULL
similar	NULL
relative	NULL
potency	NULL
data	NULL
have	NULL
been	NULL
reported	NULL
in	NULL
the	NULL
differentiation	NULL
of	NULL
rat	NULL
rhabdomyosarcoma	NULL
cells	NULL
(	NULL
34	NULL
)	NULL
.	NULL

The	NULL
relative	NULL
potency	NULL
of	NULL
these	NULL
natural	NULL
retinoids	NULL
may	NULL
,	NULL
therefore	NULL
,	NULL
be	NULL
dependent	NULL
on	NULL
the	NULL
cell	NULL
type	NULL
and	NULL
on	NULL
the	NULL
physiological	NULL
phenomenon	NULL
considered	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
relative	NULL
potency	NULL
of	NULL
ATRA	NULL
metabolites	NULL
may	NULL
also	NULL
be	NULL
biased	NULL
in	NULL
the	NULL
sense	NULL
that	NULL
the	NULL
metabolites	NULL
were	NULL
applied	NULL
exogenously	NULL
to	NULL
the	NULL
cells	NULL
,	NULL
as	NULL
opposed	NULL
to	NULL
the	NULL
physiological	NULL
situation	NULL
in	NULL
which	NULL
the	NULL
metabolites	NULL
are	NULL
formed	NULL
intracel-lularly	NULL
,	NULL
via	NULL
the	NULL
cytochrome	NULL
P450s	NULL
.	NULL

Concomitant	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
differentiation	NULL
in	NULL
the	NULL
NB4	NULL
cells	NULL
by	NULL
the	NULL
ATRA	NULL
metabolites	NULL
,	NULL
we	NULL
observed	NULL
a	NULL
reorganization	NULL
of	NULL
the	NULL
nuclear	NULL
PML-containing	NULL
bodies	NULL
,	NULL
and	NULL
a	NULL
degradation	NULL
of	NULL
the	NULL
PML-RARa	NULL
chimeric	NULL
protein	NULL
,	NULL
as	NULL
has	NULL
been	NULL
previously	NULL
observed	NULL
with	NULL
ATRA	NULL
(	NULL
51-53	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
metabolites	NULL
share	NULL
the	NULL
same	NULL
signaling	NULL
pathway	NULL
as	NULL
ATRA	NULL
.	NULL

To	NULL
verify	NULL
this	NULL
,	NULL
we	NULL
used	NULL
a	NULL
RARa-specific	NULL
antagonist	NULL
(	NULL
BMS614	NULL
)	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
metabolites	NULL
.	NULL

CD11¢	NULL
expression	NULL
analysis	NULL
showed	NULL
a	NULL
complete	NULL
inhibition	NULL
of	NULL
CD11c	NULL
expression	NULL
induction	NULL
when	NULL
NB4	NULL
cells	NULL
were	NULL
cotreated	NULL
with	NULL
BMS614	NULL
,	NULL
which	NULL
indicated	NULL
that	NULL
ATRA	NULL
metabolites	NULL
act	NULL
through	NULL
the	NULL
RARa	NULL
pathway	NULL
for	NULL
differentiation	NULL
induction	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
these	NULL
data	NULL
demonstrate	NULL
new	NULL
biological	NULL
properties	NULL
of	NULL
the	NULL
ATRA	NULL
metabolites	NULL
and	NULL
indicate	NULL
that	NULL
they	NULL
are	NULL
not	NULL
ineffective	NULL
catabolic	NULL
products	NULL
.	NULL

These	NULL
metabolites	NULL
may	NULL
participate	NULL
in	NULL
the	NULL
ATRA	NULL
mechanism	NULL
of	NULL
action	NULL
on	NULL
cell	NULL
growth	NULL
inhibition	NULL
and	NULL
differentiation	NULL
via	NULL
the	NULL
RARa	NULL
receptor	NULL
signaling	NULL
pathway	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
the	NULL
principal	NULL
ATRA	NULL
Phase	NULL
I	NULL
metabolites	NULL
are	NULL
active	NULL
retinoids	NULL
which	NULL
,	NULL
provided	NULL
that	NULL
manageable	NULL
toxicity	NULL
and	NULL
in	NULL
vivo	NULL
pharmacological	NULL
concentrations	NULL
were	NULL
achievable	NULL
,	NULL
could	NULL
be	NULL
of	NULL
interest	NULL
for	NULL
differentiation	NULL
therapy	NULL
of	NULL
sensitive	NULL
human	NULL
cancers	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
the	NULL
following	NULL
persons	NULL
who	NULL
made	NULL
these	NULL
studies	NULL
possible	NULL
:	NULL
Drs	NULL
.	NULL

Michael	NULL
Klaus	NULL
(	NULL
Hoffmann-La	NULL
Roche	NULL
Ltd.	NULL
,	NULL
Basel	NULL
,	NULL
Switzerland	NULL
)	NULL
and	NULL
Louise	NULL
H.	NULL
Foley	NULL
(	NULL
Hoffmann-La	NULL
Roche	NULL
Inc.	NULL
,	NULL
Nutley	NULL
,	NULL
NJ	NULL
)	NULL
,	NULL
who	NULL
kindly	NULL
donated	NULL
the	NULL
ATRA	NULL
metabolites	NULL
used	NULL
in	NULL
this	NULL
study	NULL
;	NULL
Prof.	NULL
Pierre	NULL
Chambon	NULL
[	NULL
Institut	NULL
de	NULL
Génétique	NULL
et	NULL
de	NULL
Biologie	NULL
Moleculaire	NULL
et	NULL
Cellulaire	NULL
(	NULL
IGBMC	NULL
,	NULL
IlIkirch	NULL
,	NULL
France	NULL
)	NULL
]	NULL
for	NULL
providing	NULL
the	NULL
anti-RARa	NULL
antibody	NULL
;	NULL
Dr.	NULL
Marcel	NULL
Koken	NULL
(	NULL
Unité	NULL
Propre	NULL
de	NULL
Recherche	NULL
9051	NULL
CNRS	NULL
,	NULL
Paris	NULL
)	NULL
for	NULL
the	NULL
PML	NULL
antibody	NULL
;	NULL
Dr.	NULL
H.	NULL
Gronemeyer	NULL
(	NULL
IGBMC	NULL
,	NULL
Illkirch	NULL
,	NULL
France	NULL
)	NULL
for	NULL
kindly	NULL
providing	NULL
the	NULL
RARa	NULL
antagonist	NULL
BMS614	NULL
;	NULL
and	NULL
Christelle	NULL
Doliger	NULL
and	NULL
Michel	NULL
Schmid	NULL
of	NULL
the	NULL
Cellular	NULL
and	NULL
Molecular	NULL
Imaging	NULL
Service	NULL
of	NULL
our	NULL
Institute	NULL
for	NULL
expert	NULL
assistance	NULL
in	NULL
image	NULL
analysis	NULL
.	NULL

704	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
2001	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

DIFFERENTIATION	NULL
OF	NULL
NB4	NULL
CELLS	NULL
BY	NULL
ATRA	NULL
METABOLITES	NULL
REFERENCES	NULL
1	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

Gudas	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
Sporn	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
and	NULL
Roberts	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

Cellular	NULL
biology	NULL
and	NULL
biochemistry	NULL
of	NULL
the	NULL
retinoids	NULL
.	NULL

In	NULL
:	NULL
M.	NULL
B.	NULL
Sporn	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Roberts	NULL
,	NULL
and	NULL
D.	NULL
S.	NULL
Goodman	NULL
(	NULL
eds	NULL
.	NULL
)	NULL

,	NULL
The	NULL
Retinoids	NULL
:	NULL
Biology	NULL
,	NULL
Chemistry	NULL
,	NULL
and	NULL
Medicine	NULL
,	NULL
pp	NULL
.	NULL

443-520	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Raven	NULL
Press	NULL
,	NULL
1994.	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Umesono	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
The	NULL
retinoid	NULL
receptors	NULL
.	NULL

In	NULL
:	NULL
M.	NULL
B.	NULL
Sporn	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Roberts	NULL
,	NULL
and	NULL
D.	NULL
S.	NULL
Goodman	NULL
(	NULL
eds	NULL
.	NULL
)	NULL

,	NULL
The	NULL
Retinoids	NULL
:	NULL
Biology	NULL
,	NULL
Chemistry	NULL
,	NULL
and	NULL
Medicine	NULL
,	NULL
pp	NULL
.	NULL

319-350	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Raven	NULL
Press	NULL
,	NULL
1994.	NULL
.	NULL

Chambon	NULL
,	NULL
P.	NULL
A	NULL
decade	NULL
of	NULL
molecular	NULL
biology	NULL
of	NULL
retinoic	NULL
acid	NULL
receptors	NULL
.	NULL

FASEB	NULL
J.	NULL
,	NULL
10	NULL
:	NULL
940-954	NULL
,	NULL
1996.	NULL
.	NULL

Kliewer	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Umesono	NULL
,	NULL
K.	NULL
,	NULL
Noonan	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Heyman	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
Convergence	NULL
of	NULL
9-cis	NULL
retinoic	NULL
acid	NULL
and	NULL
peroxisome	NULL
proliferator	NULL
signaling	NULL
pathways	NULL
through	NULL
heterodimer	NULL
formation	NULL
of	NULL
their	NULL
receptors	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
358	NULL
:	NULL
771-774	NULL
,	NULL
1992.	NULL
.	NULL

Leid	NULL
,	NULL
M.	NULL
,	NULL
Kastner	NULL
,	NULL
P.	NULL
,	NULL
Lyons	NULL
,	NULL
R.	NULL
,	NULL
Nakshatri	NULL
,	NULL
H.	NULL
,	NULL
Saunders	NULL
,	NULL
M.	NULL
,	NULL
Zacharewski	NULL
,	NULL
T.	NULL
,	NULL
Chen	NULL
,	NULL
J.	NULL
Y.	NULL
,	NULL
Staub	NULL
,	NULL
A.	NULL
,	NULL
Garnier	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Mader	NULL
,	NULL
S.	NULL
Purification	NULL
,	NULL
cloning	NULL
,	NULL
and	NULL
RXR	NULL
identity	NULL
of	NULL
the	NULL
HeLa	NULL
cell	NULL
factor	NULL
with	NULL
which	NULL
RAR	NULL
or	NULL
TR	NULL
heterodimerizes	NULL
to	NULL
bind	NULL
target	NULL
sequences	NULL
efficiently	NULL
.	NULL

Cell	NULL
,	NULL
68	NULL
:	NULL
377-395	NULL
,	NULL
1992.	NULL
.	NULL

Zhang	NULL
,	NULL
X.	NULL
K.	NULL
,	NULL
Hoffmann	NULL
,	NULL
B.	NULL
,	NULL
Tran	NULL
,	NULL
P.	NULL
B.	NULL
,	NULL
Graupner	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Pfahl	NULL
,	NULL
M.	NULL
Retinoid	NULL
X	NULL
receptor	NULL
is	NULL
an	NULL
auxiliary	NULL
protein	NULL
for	NULL
thyroid	NULL
hormone	NULL
and	NULL
retinoic	NULL
acid	NULL
receptors	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
355	NULL
:	NULL
441-446	NULL
,	NULL
1992.	NULL
.	NULL

Kastner	NULL
,	NULL
P.	NULL
,	NULL
Mark	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Chambon	NULL
,	NULL
P.	NULL
Nonsteroid	NULL
nuclear	NULL
receptors	NULL
:	NULL
what	NULL
are	NULL
genetic	NULL
studies	NULL
telling	NULL
us	NULL
about	NULL
their	NULL
role	NULL
in	NULL
real	NULL
life	NULL
?	NULL

Cell	NULL
,	NULL
83	NULL
:	NULL
859-869	NULL
,	NULL
1995.	NULL
.	NULL

Mangelsdorf	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
The	NULL
RXR	NULL
heterodimers	NULL
and	NULL
orphan	NULL
receptors	NULL
.	NULL

Cell	NULL
,	NULL
83	NULL
:	NULL
841-850	NULL
,	NULL
1995.	NULL
.	NULL

Dekker	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
Vaessen	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
van	NULL
den	NULL
Berg	NULL
,	NULL
C.	NULL
,	NULL
Timmermans	NULL
,	NULL
A.	NULL
,	NULL
Godsave	NULL
,	NULL
S.	NULL
,	NULL
Holling	NULL
,	NULL
T.	NULL
,	NULL
Nieuwkoop	NULL
,	NULL
P.	NULL
,	NULL
Geurts	NULL
van	NULL
Kessel	NULL
,	NULL
A.	NULL
and	NULL
Durston	NULL
,	NULL
A.	NULL
Overexpression	NULL
of	NULL
a	NULL
cellular	NULL
retinoic	NULL
acid	NULL
binding	NULL
protein	NULL
(	NULL
xCRABP	NULL
)	NULL
causes	NULL
anteroposterior	NULL
defects	NULL
in	NULL
developing	NULL
Xenopus	NULL
embryos	NULL
.	NULL

Development	NULL
(	NULL
Cambridge	NULL
)	NULL
,	NULL
120	NULL
:	NULL
973-985	NULL
,	NULL
1994	NULL
.	NULL

Glass	NULL
,	NULL
C.	NULL
K.	NULL
,	NULL
Rose	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
and	NULL
Rosenfeld	NULL
,	NULL
M.	NULL
G.	NULL
Nuclear	NULL
receptor	NULL
coactivators	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

,	NULL
9	NULL
:	NULL
222-232	NULL
,	NULL
1997	NULL
.	NULL

Hong	NULL
,	NULL
W.	NULL
K.	NULL
,	NULL
and	NULL
Ttri	NULL
,	NULL
L.	NULL
M.	NULL
Retinoids	NULL
and	NULL
human	NULL
cancer	NULL
.	NULL

/n	NULL
:	NULL
M.	NULL
B.	NULL
Sporn	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Roberts	NULL
and	NULL
D.	NULL
S.	NULL
Goodman	NULL
(	NULL
eds	NULL
.	NULL
)	NULL

,	NULL
The	NULL
Retinoids	NULL
:	NULL
Biology	NULL
,	NULL
Chemistry	NULL
,	NULL
and	NULL
Medicine	NULL
,	NULL
pp	NULL
.	NULL

597-630	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Raven	NULL
Press	NULL
,	NULL
1994	NULL
.	NULL

Huang	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Ye	NULL
,	NULL
Y.	NULL
C.	NULL
,	NULL
Chen	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Chai	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Lu	NULL
,	NULL
J.	NULL
X.	NULL
,	NULL
Zhoa	NULL
,	NULL
L.	NULL
,	NULL
Gu	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
and	NULL
Wang	NULL
,	NULL
Z.	NULL
Y	NULL
.	NULL

Use	NULL
of	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Blood	NULL
,	NULL
72	NULL
:	NULL
567-572	NULL
,	NULL
1988.	NULL
de	NULL
The	NULL
,	NULL
H.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Lanotte	NULL
,	NULL
M.	NULL
,	NULL
Degos	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Dejean	NULL
,	NULL
A	NULL
.	NULL

The	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
fuses	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
alpha	NULL
gene	NULL
to	NULL
a	NULL
novel	NULL
transcribed	NULL
locus	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
347	NULL
:	NULL
558-561	NULL
,	NULL
1990	NULL
.	NULL

Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Zangrilli	NULL
,	NULL
D.	NULL
,	NULL
Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Longo	NULL
,	NULL
L.	NULL
,	NULL
Mencarelli	NULL
,	NULL
A.	NULL
,	NULL
Giacomucci	NULL
,	NULL
A.	NULL
,	NULL
Rocchi	NULL
,	NULL
M.	NULL
,	NULL
Biondi	NULL
,	NULL
A.	NULL
,	NULL
Rambaldi	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Lo	NULL
,	NULL
C.	NULL
F.	NULL
Translocation	NULL
breakpoint	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
lies	NULL
within	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
locus	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
88	NULL
:	NULL
1977-1981	NULL
,	NULL
1991	NULL
.	NULL

Borrow	NULL
,	NULL
J.	NULL
,	NULL
Goddard	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Sheer	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Solomon	NULL
,	NULL
E.	NULL
Molecular	NULL
analysis	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
breakpoint	NULL
cluster	NULL
region	NULL
on	NULL
chromosome	NULL
17	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
,	NULL
249	NULL
:	NULL
1577-1580	NULL
,	NULL
1990	NULL
.	NULL

Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Grignani	NULL
,	NULL
F.	NULL
,	NULL
Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Mencarelli	NULL
,	NULL
A.	NULL
,	NULL
Biondi	NULL
,	NULL
A.	NULL
,	NULL
LoCoco	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
Structure	NULL
and	NULL
origin	NULL
of	NULL
the	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
myl/RAR	NULL
a	NULL
cDNA	NULL
and	NULL
characterization	NULL
of	NULL
its	NULL
retinoid-binding	NULL
and	NULL
transactivation	NULL
properties	NULL
.	NULL

Oncogene	NULL
,	NULL
6	NULL
:	NULL
1285-1292	NULL
,	NULL
1991	NULL
.	NULL

Kakizuka	NULL
,	NULL
A.	NULL
,	NULL
Miller	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Jr.	NULL
,	NULL
Umesono	NULL
,	NULL
K.	NULL
,	NULL
Warrell	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
,	NULL
Frankel	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Murty	NULL
,	NULL
V.	NULL
V.	NULL
,	NULL
Dmitrovsky	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
Chromosomal	NULL
translocation	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
in	NULL
human	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
fuses	NULL
RAR	NULL
a	NULL
with	NULL
a	NULL
novel	NULL
putative	NULL
transcription	NULL
factor	NULL
,	NULL
PML	NULL
.	NULL

Cell	NULL
,	NULL
66	NULL
:	NULL
663-674	NULL
,	NULL
1991	NULL
.	NULL

Kastner	NULL
,	NULL
P.	NULL
,	NULL
Perez	NULL
,	NULL
A.	NULL
,	NULL
Lutz	NULL
,	NULL
Y.	NULL
,	NULL
Rochette-Egly	NULL
,	NULL
C.	NULL
,	NULL
Gaub	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Durand	NULL
,	NULL
B.	NULL
,	NULL
Lanotte	NULL
,	NULL
M.	NULL
,	NULL
Berger	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Chambon	NULL
,	NULL
P.	NULL
Structure	NULL
,	NULL
localization	NULL
and	NULL
transcriptional	NULL
properties	NULL
of	NULL
two	NULL
classes	NULL
of	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
fusion	NULL
proteins	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
:	NULL
structural	NULL
similarities	NULL
with	NULL
a	NULL
new	NULL
family	NULL
of	NULL
oncoproteins	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
11	NULL
:	NULL
629-642	NULL
,	NULL
1992	NULL
.	NULL

Fenaux	NULL
,	NULL
P.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Degos	NULL
,	NULL
L.	NULL
Acute	NULL
promyelocytic	NULL
leukemia	NULL
:	NULL
biology	NULL
and	NULL
treatment	NULL
.	NULL

Semin	NULL
.	NULL

Oncol	NULL
.	NULL

,	NULL
24	NULL
:	NULL
92-102	NULL
,	NULL
1997	NULL
.	NULL

Warrell	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
Retinoid	NULL
resistance	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
:	NULL
new	NULL
mech-anisms	NULL
,	NULL
strategies	NULL
,	NULL
and	NULL
implications	NULL
.	NULL

Blood	NULL
,	NULL
82	NULL
:	NULL
1949-1953	NULL
,	NULL
1993	NULL
.	NULL

Muindi	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Frankel	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Huselton	NULL
,	NULL
C.	NULL
,	NULL
DeGrazia	NULL
,	NULL
F.	NULL
,	NULL
Garland	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
Young	NULL
,	NULL
C.	NULL
W.	NULL
,	NULL
and	NULL
Warrell	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
Clinical	NULL
pharmacology	NULL
of	NULL
oral	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
in	NULL
patients	NULL
with	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
52	NULL
:	NULL
2138-2142	NULL
,	NULL
1992	NULL
.	NULL

Rigas	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Francis	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Muindi	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Kris	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Huselton	NULL
,	NULL
C.	NULL
,	NULL
DeGrazia	NULL
,	NULL
F.	NULL
,	NULL
Orazem	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Young	NULL
,	NULL
C.	NULL
W.	NULL
,	NULL
and	NULL
Warrell	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
Constitutive	NULL
variability	NULL
in	NULL
the	NULL
pharmacokinetics	NULL
of	NULL
the	NULL
natural	NULL
retinoid	NULL
,	NULL
all-frans-retinoic	NULL
acid	NULL
,	NULL
and	NULL
its	NULL
modulation	NULL
by	NULL
ketoconazole	NULL
.	NULL

J.	NULL
Natl	NULL
.	NULL

Cancer	NULL
Inst	NULL
.	NULL

,	NULL
85	NULL
:	NULL
1921-1926	NULL
,	NULL
1993	NULL
.	NULL

Conley	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Egorin	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Sridhara	NULL
,	NULL
R.	NULL
,	NULL
Finley	NULL
,	NULL
R.	NULL
,	NULL
Hemady	NULL
,	NULL
R.	NULL
,	NULL
Wu	NULL
,	NULL
S.	NULL
,	NULL
Tait	NULL
,	NULL
N.	NULL
S.	NULL
,	NULL
and	NULL
Van	NULL
Echo	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

Phase	NULL
I	NULL
clinical	NULL
trial	NULL
of	NULL
all-trans-retinoic	NULL
acid	NULL
with	NULL
correlation	NULL
of	NULL
its	NULL
pharmacokinetics	NULL
and	NULL
pharmacodynamics	NULL
.	NULL

Cancer	NULL
Chemother	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
39	NULL
:	NULL
291-299	NULL
,	NULL
1997	NULL
.	NULL

Cornic	NULL
,	NULL
M.	NULL
,	NULL
Delva	NULL
,	NULL
L.	NULL
,	NULL
Guidez	NULL
,	NULL
F.	NULL
,	NULL
Balitrand	NULL
,	NULL
N.	NULL
,	NULL
Degos	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Chomienne	NULL
,	NULL
C.	NULL
Induction	NULL
of	NULL
retinoic	NULL
acid-binding	NULL
protein	NULL
in	NULL
normal	NULL
and	NULL
malignant	NULL
human	NULL
myeloid	NULL
cells	NULL
by	NULL
retinoic	NULL
acid	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
patients	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
52	NULL
:	NULL
3329-3334	NULL
,	NULL
1992	NULL
.	NULL

Shao	NULL
,	NULL
W.	NULL
,	NULL
Benedetti	NULL
,	NULL
L.	NULL
,	NULL
Lamph	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Nervi	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Miller	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Jr.	NULL
A	NULL
retinoid-resistant	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
subclone	NULL
expresses	NULL
a	NULL
dominant	NULL
negative	NULL
PML-RAR	NULL
a	NULL
mutation	NULL
.	NULL

Blood	NULL
,	NULL
89	NULL
:	NULL
4282-4289	NULL
,	NULL
1997	NULL
.	NULL

Kitamura	NULL
,	NULL
K.	NULL
,	NULL
Kiyoi	NULL
,	NULL
H.	NULL
,	NULL
Yoshida	NULL
,	NULL
H.	NULL
,	NULL
Saito	NULL
,	NULL
H.	NULL
,	NULL
Ohno	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Naoe	NULL
,	NULL
T.	NULL
Mutant	NULL
AF-2	NULL
domain	NULL
of	NULL
PML-RARa	NULL
:	NULL
in	NULL
retinoic	NULL
acid-resistant	NULL
NB4	NULL
cells	NULL
:	NULL
differentiation	NULL
induced	NULL
by	NULL
RA	NULL
is	NULL
triggered	NULL
directly	NULL
through	NULL
PML-	NULL
RARa	NULL
and	NULL
its	NULL
down-regulation	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Leukemia	NULL
(	NULL
Baltimore	NULL
)	NULL
,	NULL
17	NULL
:	NULL
1950-1956	NULL
,	NULL
1997	NULL
.	NULL

Imaizumi	NULL
,	NULL
M.	NULL
,	NULL
Suzuki	NULL
,	NULL
H.	NULL
,	NULL
Yoshinari	NULL
,	NULL
M.	NULL
,	NULL
Sato	NULL
,	NULL
A.	NULL
,	NULL
Saito	NULL
,	NULL
T.	NULL
,	NULL
Sugawara	NULL
,	NULL
A.	NULL
,	NULL
Tsuchiya	NULL
,	NULL
S.	NULL
,	NULL
Hatae	NULL
,	NULL
Y.	NULL
,	NULL
Fujimoto	NULL
,	NULL
T.	NULL
,	NULL
Kakizuka	NULL
,	NULL
A.	NULL
,	NULL
Konno	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Iinuma	NULL
,	NULL
K.	NULL
Mutations	NULL
in	NULL
the	NULL
E-domain	NULL
of	NULL
RAR	NULL
portion	NULL
of	NULL
the	NULL
PML/RAR	NULL
chimeric	NULL
gene	NULL
may	NULL
confer	NULL
clinical	NULL
705	NULL
28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53.	NULL
resistance	NULL
to	NULL
all-frans	NULL
retinoic	NULL
acid	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Blood	NULL
,	NULL
92	NULL
:	NULL
374-382	NULL
,	NULL
1998	NULL
.	NULL

Ding	NULL
,	NULL
W.	NULL
,	NULL
Li	NULL
,	NULL
Y.	NULL
P.	NULL
,	NULL
Nobile	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Grills	NULL
,	NULL
G.	NULL
,	NULL
Carrera	NULL
,	NULL
I.	NULL
,	NULL
Paietta	NULL
,	NULL
E.	NULL
,	NULL
Tallman	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
Wiemik	NULL
,	NULL
P.	NULL
H.	NULL
,	NULL
and	NULL
Gallagher	NULL
,	NULL
R.	NULL
E.	NULL
Leukemic	NULL
cellular	NULL
retinoic	NULL
acid	NULL
resistance	NULL
and	NULL
missense	NULL
mutations	NULL
in	NULL
the	NULL
PML-RARa	NULL
:	NULL
fusion	NULL
gene	NULL
after	NULL
relapse	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
from	NULL
treatment	NULL
with	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
and	NULL
intensive	NULL
chemother-apy	NULL
.	NULL

Blood	NULL
,	NULL
92	NULL
:	NULL
1172-1183	NULL
,	NULL
1998	NULL
.	NULL

Duprez	NULL
,	NULL
E.	NULL
,	NULL
Benoit	NULL
,	NULL
G.	NULL
,	NULL
Flexor	NULL
,	NULL
M.	NULL
,	NULL
Lillehaug	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
and	NULL
Lanotte	NULL
,	NULL
M.	NULL
A	NULL
mutated	NULL
PML/RARA	NULL
found	NULL
in	NULL
the	NULL
retinoid	NULL
maturation	NULL
resistant	NULL
NB4	NULL
subclone	NULL
,	NULL
NB4-R2	NULL
,	NULL
blocks	NULL
RARA	NULL
,	NULL
and	NULL
wild-type	NULL
PML/RARA	NULL
transcriptional	NULL
activities	NULL
.	NULL

Leukemia	NULL
(	NULL
Baltimore	NULL
)	NULL
,	NULL
14	NULL
:	NULL
255-261	NULL
,	NULL
2000	NULL
.	NULL

Blaner	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
and	NULL
Olson	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Retinol	NULL
and	NULL
retinoic	NULL
acid	NULL
metabolism	NULL
.	NULL

/n	NULL
:	NULL
M.	NULL
B.	NULL
Sporn	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Roberts	NULL
and	NULL
D.	NULL
S.	NULL
Goodman	NULL
(	NULL
eds	NULL
.	NULL
)	NULL

,	NULL
The	NULL
Retinoids	NULL
:	NULL
Biology	NULL
,	NULL
Chemistry	NULL
,	NULL
and	NULL
Medicine	NULL
,	NULL
pp	NULL
.	NULL

229-256	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Raven	NULL
Press	NULL
,	NULL
1994	NULL
.	NULL

Pijnappel	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Hendriks	NULL
,	NULL
H.	NULL
F.	NULL
,	NULL
Folkers	NULL
,	NULL
G.	NULL
E.	NULL
,	NULL
van	NULL
den	NULL
Brink	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
Dekker	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
Edelenbosch	NULL
,	NULL
C.	NULL
,	NULL
van	NULL
der	NULL
Saag	NULL
,	NULL
P.	NULL
T.	NULL
,	NULL
and	NULL
Durston	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

The	NULL
retinoid	NULL
ligand	NULL
4-oxo-retinoic	NULL
acid	NULL
is	NULL
a	NULL
highly	NULL
active	NULL
modulator	NULL
of	NULL
positional	NULL
specification	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
366	NULL
:	NULL
340-344	NULL
,	NULL
1993	NULL
.	NULL

Reynolds	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Fisher	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Griffiths	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
Tavakkol	NULL
,	NULL
A.	NULL
,	NULL
Talwar	NULL
,	NULL
H.	NULL
S.	NULL
,	NULL
Rowse	NULL
,	NULL
P.	NULL
E.	NULL
,	NULL
Hamilton	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Voorhees	NULL
,	NULL
J.	NULL
J.	NULL
Retinoic	NULL
acid	NULL
metabolites	NULL
exhibit	NULL
biological	NULL
activity	NULL
in	NULL
human	NULL
keratinocytes	NULL
,	NULL
mouse	NULL
melanoma	NULL
cells	NULL
,	NULL
and	NULL
hairless	NULL
mouse	NULL
skin	NULL
in	NULL
vivo	NULL
.	NULL

J.	NULL
Pharmacol	NULL
.	NULL

Exp	NULL
.	NULL

Ther	NULL
.	NULL

,	NULL
266	NULL
:	NULL
1636-1642	NULL
,	NULL
1993.	NULL
van	NULL
Heusden	NULL
,	NULL
J.	NULL
,	NULL
Wouters	NULL
,	NULL
W.	NULL
,	NULL
Ramaekers	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
Krekels	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
Dillen	NULL
,	NULL
L.	NULL
,	NULL
Borgers	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Smets	NULL
,	NULL
G.	NULL
All-frans-retinoic	NULL
acid	NULL
metabolites	NULL
significantly	NULL
inhibit	NULL
the	NULL
proliferation	NULL
of	NULL
MCF-7	NULL
human	NULL
breast	NULL
cancer	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
77	NULL
:	NULL
26-32	NULL
,	NULL
1998	NULL
.	NULL

Ramp	NULL
,	NULL
U.	NULL
,	NULL
Gerharz	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Eifler	NULL
,	NULL
E.	NULL
,	NULL
Biesalski	NULL
,	NULL
H.	NULL
K.	NULL
,	NULL
and	NULL
Gabbert	NULL
,	NULL
H.	NULL
E.	NULL
Effects	NULL
of	NULL
retinoic	NULL
acid	NULL
metabolites	NULL
on	NULL
proliferation	NULL
and	NULL
differentiation	NULL
of	NULL
the	NULL
clonal	NULL
rhabdomyosarcoma	NULL
cell	NULL
line	NULL
BA-HAN-1C	NULL
.	NULL

Biol	NULL
.	NULL

Cell	NULL
,	NULL
87	NULL
:	NULL
31-37	NULL
,	NULL
1994.	NULL
van	NULL
der	NULL
Leede	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
van	NULL
den	NULL
Brink	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
Pijnappel	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Sonneveld	NULL
,	NULL
E.	NULL
,	NULL
van	NULL
der	NULL
Saag	NULL
,	NULL
P.	NULL
T.	NULL
,	NULL
and	NULL
van	NULL
der	NULL
Burg	NULL
,	NULL
B.	NULL
Autoinduction	NULL
of	NULL
retinoic	NULL
acid	NULL
metabolism	NULL
to	NULL
polar	NULL
derivatives	NULL
with	NULL
decreased	NULL
biological	NULL
activity	NULL
in	NULL
retinoic	NULL
acid-sensitive	NULL
,	NULL
but	NULL
not	NULL
in	NULL
retinoic	NULL
acid-resistant	NULL
human	NULL
breast	NULL
cancer	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
272	NULL
:	NULL
17921-17928	NULL
,	NULL
1997	NULL
.	NULL

Duell	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Astrom	NULL
,	NULL
A.	NULL
,	NULL
Griffiths	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
Chambon	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Voorhees	NULL
,	NULL
J.	NULL
J	NULL
.	NULL

Human	NULL
skin	NULL
levels	NULL
of	NULL
retinoic	NULL
acid	NULL
and	NULL
cytochrome	NULL
P-450-derived	NULL
4-	NULL
hydroxyretinoic	NULL
acid	NULL
after	NULL
topical	NULL
application	NULL
of	NULL
retinoic	NULL
acid	NULL
in	NULL
vivo	NULL
compared	NULL
with	NULL
concentrations	NULL
required	NULL
to	NULL
stimulate	NULL
retinoic	NULL
acid	NULL
receptor-mediated	NULL
transcription	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
90	NULL
:	NULL
1269-1274	NULL
,	NULL
1992	NULL
.	NULL

Takatsuka	NULL
,	NULL
J.	NULL
,	NULL
Takahashi	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
De	NULL
Luca	NULL
,	NULL
L.	NULL
M.	NULL
Retinoic	NULL
acid	NULL
metabolism	NULL
and	NULL
inhibition	NULL
of	NULL
cell	NULL
proliferation	NULL
:	NULL
an	NULL
unexpected	NULL
liaison	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
56	NULL
:	NULL
675-678	NULL
,	NULL
1996	NULL
.	NULL

Lanotte	NULL
,	NULL
M.	NULL
,	NULL
Martin-Thouvenin	NULL
,	NULL
V.	NULL
,	NULL
Najman	NULL
,	NULL
S.	NULL
,	NULL
Balerini	NULL
,	NULL
P.	NULL
,	NULL
Valensi	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Berger	NULL
,	NULL
R.	NULL
NB4	NULL
,	NULL
a	NULL
maturation	NULL
inducible	NULL
cell	NULL
line	NULL
with	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
marker	NULL
isolated	NULL
from	NULL
a	NULL
human	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
M3	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
77	NULL
:	NULL
1080-1086	NULL
,	NULL
1991	NULL
.	NULL

Gubler	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
and	NULL
Sherman	NULL
,	NULL
M.	NULL
I.	NULL
Metabolism	NULL
of	NULL
retinoic	NULL
acid	NULL
and	NULL
retinol	NULL
by	NULL
intact	NULL
cells	NULL
and	NULL
cell	NULL
extracts	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

,	NULL
189	NULL
:	NULL
525-530	NULL
,	NULL
1990	NULL
.	NULL

Koken	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Puvion-Dutilleul	NULL
,	NULL
F.	NULL
,	NULL
Guillemin	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Viron	NULL
,	NULL
A.	NULL
,	NULL
Linares-Cruz	NULL
,	NULL
G.	NULL
,	NULL
Stuurman	NULL
,	NULL
N.	NULL
,	NULL
de	NULL
Jong	NULL
,	NULL
L.	NULL
,	NULL
Szostecki	NULL
,	NULL
C.	NULL
,	NULL
Calvo	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Chomienne	NULL
,	NULL
C.	NULL
The	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
alters	NULL
a	NULL
nuclear	NULL
body	NULL
in	NULL
a	NULL
retinoic	NULL
acid-reversible	NULL
fashion	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
13	NULL
:	NULL
1073-1083	NULL
,	NULL
1994	NULL
.	NULL

Benoit	NULL
,	NULL
G.	NULL
,	NULL
Altucci	NULL
,	NULL
L.	NULL
,	NULL
Flexor	NULL
,	NULL
M.	NULL
,	NULL
Ruchaud	NULL
,	NULL
S.	NULL
,	NULL
Lillchaug	NULL
,	NULL
J.	NULL
,	NULL
Raffelsberger	NULL
,	NULL
W.	NULL
,	NULL
Gronemeyer	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Lanotte	NULL
,	NULL
M.	NULL
RAR-independent	NULL
RXR	NULL
signaling	NULL
induces	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
leukemia	NULL
cell	NULL
maturation	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
18	NULL
:	NULL
7011-7018	NULL
,	NULL
1999	NULL
.	NULL

Duprez	NULL
,	NULL
E.	NULL
,	NULL
Lillchaug	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Nave	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Lanotte	NULL
,	NULL
M.	NULL
cAMP	NULL
signaling	NULL
is	NULL
decisive	NULL
for	NULL
recovery	NULL
of	NULL
nuclear	NULL
bodies	NULL
(	NULL
PODs	NULL
)	NULL
during	NULL
maturation	NULL
of	NULL
RA-resistant	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
promyelocytic	NULL
leukemia	NULL
NB4	NULL
cells	NULL
expressing	NULL
PML-RAR	NULL
a.	NULL
Oncogene	NULL
,	NULL
12	NULL
;	NULL
2451-2459	NULL
,	NULL
1996	NULL
.	NULL

Muindi	NULL
,	NULL
J.	NULL
,	NULL
Frankel	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Miller	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Jr.	NULL
,	NULL
Jakubowski	NULL
,	NULL
A.	NULL
,	NULL
Scheinberg	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Young	NULL
,	NULL
C.	NULL
W.	NULL
,	NULL
Dmitrovsky	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Warrell	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr	NULL
.	NULL

Continuous	NULL
treatment	NULL
with	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
causes	NULL
a	NULL
progressive	NULL
reduction	NULL
in	NULL
plasma	NULL
drug	NULL
concentrations	NULL
:	NULL
implications	NULL
for	NULL
relapse	NULL
and	NULL
retinoid	NULL
``	NULL
resistance	NULL
``	NULL
in	NULL
patients	NULL
with	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Blood	NULL
,	NULL
79	NULL
:	NULL
299-303	NULL
,	NULL
1992.	NULL
van	NULL
der	NULL
Burg	NULL
,	NULL
B.	NULL
,	NULL
Sonneveld	NULL
,	NULL
E.	NULL
,	NULL
Lemmen	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
and	NULL
van	NULL
der	NULL
Saag	NULL
,	NULL
P.	NULL
T.	NULL
Morpho-genetic	NULL
action	NULL
of	NULL
retinoids	NULL
and	NULL
estrogens	NULL
.	NULL

Int	NULL
.	NULL

J.	NULL
Dev	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
43	NULL
:	NULL
735-743	NULL
,	NULL
1999	NULL
.	NULL

Leo	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Lasker	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Raucy	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Kim	NULL
,	NULL
C.	NULL
I.	NULL
,	NULL
Black	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Lieber	NULL
,	NULL
C.	NULL
S.	NULL
Metabolism	NULL
of	NULL
retinol	NULL
and	NULL
retinoic	NULL
acid	NULL
by	NULL
human	NULL
liver	NULL
cytochrome	NULL
P45OIICS8	NULL
.	NULL

Arch	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

,	NULL
269	NULL
:	NULL
305-312	NULL
,	NULL
1989	NULL
.	NULL

White	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Petkovich	NULL
,	NULL
M.	NULL
Identification	NULL
and	NULL
cloning	NULL
of	NULL
RA-regulated	NULL
genes	NULL
by	NULL
mRNA-differential	NULL
display	NULL
.	NULL

In	NULL
:	NULL
C.	NULL
P.	NULL
F.	NULL
Redfern	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Retinoid	NULL
Protocols	NULL
,	NULL
pp	NULL
.	NULL

389-404	NULL
.	NULL

Totowa	NULL
,	NULL
New	NULL
Jersey	NULL
:	NULL
Humana	NULL
Press	NULL
,	NULL
1998	NULL
.	NULL

White	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Beckett-Jones	NULL
,	NULL
B.	NULL
,	NULL
Guo	NULL
,	NULL
Y.	NULL
D.	NULL
,	NULL
Dilworth	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
Bonasoro	NULL
,	NULL
J.	NULL
,	NULL
Jones	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Petkovich	NULL
,	NULL
M.	NULL
cDNA	NULL
cloning	NULL
of	NULL
human	NULL
retinoic	NULL
acid-metabolizing	NULL
enzyme	NULL
(	NULL
RP4S50RAT	NULL
)	NULL
identifies	NULL
a	NULL
novel	NULL
family	NULL
of	NULL
cytochromes	NULL
P450	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
272	NULL
:	NULL
18538-18541	NULL
,	NULL
1997	NULL
.	NULL

Napoli	NULL
,	NULL
J.	NULL
L.	NULL
Retinoic	NULL
acid	NULL
:	NULL
its	NULL
biosynthesis	NULL
and	NULL
metabolism	NULL
.	NULL

Prog	NULL
.	NULL

Nucleic	NULL
Acid	NULL
Res	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
63	NULL
:	NULL
139-188	NULL
,	NULL
1999	NULL
.	NULL

Marill	NULL
,	NULL
J.	NULL
,	NULL
Cresteil	NULL
,	NULL
T.	NULL
,	NULL
Lanotte	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Chabot	NULL
,	NULL
G.	NULL
G.	NULL
Identification	NULL
of	NULL
human	NULL
cytochrome	NULL
P450s	NULL
involved	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
all-trans-retinoic	NULL
acid	NULL
principal	NULL
metabolites	NULL
.	NULL

Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
58	NULL
:	NULL
1341-1348	NULL
,	NULL
2000	NULL
.	NULL

Muindi	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Young	NULL
,	NULL
C.	NULL
W.	NULL
,	NULL
and	NULL
Warrell	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
Clinical	NULL
pharmacology	NULL
of	NULL
all-frans	NULL
retinoic	NULL
acid	NULL
.	NULL

Leukemia	NULL
(	NULL
Baltimore	NULL
)	NULL
,	NULL
8	NULL
:	NULL
1807-1812	NULL
,	NULL
1994	NULL
.	NULL

Duprez	NULL
,	NULL
E.	NULL
,	NULL
Lillchaug	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Gaub	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
and	NULL
Lanotte	NULL
,	NULL
M.	NULL
Differential	NULL
changes	NULL
of	NULL
retinoid-X-receptor	NULL
(	NULL
RXR	NULL
a	NULL
)	NULL
and	NULL
its	NULL
RAR	NULL
alpha	NULL
and	NULL
PML-RAR	NULL
a	NULL
partners	NULL
induced	NULL
by	NULL
retinoic	NULL
acid	NULL
and	NULL
cAMP	NULL
distinguish	NULL
maturation	NULL
sensitive	NULL
and	NULL
resistant	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
promyelocytic	NULL
leukemia	NULL
NB4	NULL
cells	NULL
.	NULL

Oncogene	NULL
,	NULL
12	NULL
:	NULL
2443-2450	NULL
,	NULL
1996	NULL
.	NULL

Yoshida	NULL
,	NULL
H.	NULL
,	NULL
Kitamura	NULL
,	NULL
K.	NULL
,	NULL
Tanaka	NULL
,	NULL
K.	NULL
,	NULL
Omura	NULL
,	NULL
S.	NULL
,	NULL
Miyazaki	NULL
,	NULL
T.	NULL
,	NULL
Hachiya	NULL
,	NULL
T.	NULL
,	NULL
Ohno	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Naoe	NULL
,	NULL
T.	NULL
Accelerated	NULL
degradation	NULL
of	NULL
PML-retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
(	NULL
PML-RARA	NULL
)	NULL
oncoprotein	NULL
by	NULL
all-frans-retinoic	NULL
acid	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
:	NULL
possible	NULL
role	NULL
of	NULL
the	NULL
proteasome	NULL
pathway	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
56	NULL
:	NULL
2945-2948	NULL
,	NULL
1996	NULL
.	NULL

Raelson	NULL
,	NULL
J.	NULL
V.	NULL
,	NULL
Nervi	NULL
,	NULL
C.	NULL
,	NULL
Rosenauer	NULL
,	NULL
A.	NULL
,	NULL
Benedetti	NULL
,	NULL
L.	NULL
,	NULL
Monezak	NULL
,	NULL
Y.	NULL
,	NULL
Pearson	NULL
,	NULL
M.	NULL
,	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
and	NULL
Miller	NULL
,	NULL
W.	NULL
H.	NULL
J	NULL
.	NULL

The	NULL
PML/RAR	NULL
a	NULL
oncoprotein	NULL
is	NULL
a	NULL
direct	NULL
molecular	NULL
target	NULL
of	NULL
retinoic	NULL
acid	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
.	NULL

Blood	NULL
,	NULL
88	NULL
:	NULL
2826-2832	NULL
,	NULL
1996	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
2001	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAC	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
Granulocytic	NULL
Differentiation	NULL
of	NULL
Human	NULL
NB4	NULL
Promyelocytic	NULL
Leukemia	NULL
Cells	NULL
Induced	NULL
by	NULL
All-	NULL
trans	NULL
Retinoic	NULL
Acid	NULL
Metabolites	NULL
Nadia	NULL
Idres	NULL
,	NULL
Gérard	NULL
Benoi	NULL
?	NULL

t	NULL
,	NULL
Maria	NULL
A.	NULL
Flexor	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cancer	NULL
Res	NULL
2001	NULL
;	NULL
61:700-705	NULL
.	NULL

Updated	NULL
version	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/61/2/700	NULL
Cited	NULL
articles	NULL
Citing	NULL
articles	NULL
This	NULL
article	NULL
cites	NULL
46	NULL
articles	NULL
,	NULL
20	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/61/2/700	NULL
full	NULL
#	NULL
ref-list-1	NULL
This	NULL
article	NULL
has	NULL
been	NULL
cited	NULL
by	NULL
11	NULL
HighWire-hosted	NULL
articles	NULL
.	NULL

Access	NULL
the	NULL
articles	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/61/2/700	NULL
full	NULL
#	NULL
related-urls	NULL
E-mail	NULL
alerts	NULL
Reprints	NULL
and	NULL
Subscriptions	NULL
Permissions	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/61/2/700	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
2001	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

